<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Modeling COVID-19 disease processes by remote elicitation of causal Bayesian networks from medical experts</title>
				<funder ref="#_9Pbrayv">
					<orgName type="full">Snow Medical Research Foundation</orgName>
				</funder>
				<funder>
					<orgName type="full">Digital Health CRC</orgName>
				</funder>
				<funder>
					<orgName type="full">Australian Commonwealth Government&apos;s Cooperative Research Centres Programme</orgName>
				</funder>
				<funder ref="#_YBZ4uFw">
					<orgName type="full">unknown</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
				</availability>
				<date type="published" when="2022-02-14">February 14, 2022</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Steven</forename><surname>Mascaro</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Faculty of Information Technology</orgName>
								<orgName type="institution">Monash University</orgName>
								<address>
									<postCode>3168</postCode>
									<settlement>Clayton</settlement>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">Bayesian Intelligence Pty Ltd</orgName>
								<address>
									<postCode>3158</postCode>
									<settlement>Upwey</settlement>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yue</forename><surname>Wu</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">School of Public Health</orgName>
								<orgName type="institution">University of Sydney</orgName>
								<address>
									<postCode>2006</postCode>
									<settlement>Camperdown</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Owen</forename><surname>Woodberry</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Faculty of Information Technology</orgName>
								<orgName type="institution">Monash University</orgName>
								<address>
									<postCode>3168</postCode>
									<settlement>Clayton</settlement>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">Bayesian Intelligence Pty Ltd</orgName>
								<address>
									<postCode>3158</postCode>
									<settlement>Upwey</settlement>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Erik</forename><forename type="middle">P</forename><surname>Nyberg</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Faculty of Information Technology</orgName>
								<orgName type="institution">Monash University</orgName>
								<address>
									<postCode>3168</postCode>
									<settlement>Clayton</settlement>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ross</forename><surname>Pearson</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Faculty of Information Technology</orgName>
								<orgName type="institution">Monash University</orgName>
								<address>
									<postCode>3168</postCode>
									<settlement>Clayton</settlement>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jessica</forename><surname>Ramsay</surname></persName>
							<affiliation key="aff3">
								<orgName type="laboratory">Wesfarmers Centre of Vaccines and Infectious Diseases</orgName>
								<orgName type="institution" key="instit1">Telethon Kids Institute</orgName>
								<orgName type="institution" key="instit2">University of Western Australia</orgName>
								<address>
									<postCode>6009</postCode>
									<settlement>Nedlands</settlement>
									<region>WA</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ariel</forename><surname>Mace</surname></persName>
							<affiliation key="aff3">
								<orgName type="laboratory">Wesfarmers Centre of Vaccines and Infectious Diseases</orgName>
								<orgName type="institution" key="instit1">Telethon Kids Institute</orgName>
								<orgName type="institution" key="instit2">University of Western Australia</orgName>
								<address>
									<postCode>6009</postCode>
									<settlement>Nedlands</settlement>
									<region>WA</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Department of General Paediatrics</orgName>
								<orgName type="institution">Perth Children&apos;s Hospital</orgName>
								<address>
									<postCode>6009</postCode>
									<settlement>Nedlands</settlement>
									<region>WA</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">Department of Paediatrics</orgName>
								<orgName type="institution">Fiona Stanley Hospital</orgName>
								<address>
									<postCode>6150</postCode>
									<settlement>Murdoch</settlement>
									<region>WA</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Foley</surname></persName>
							<affiliation key="aff3">
								<orgName type="laboratory">Wesfarmers Centre of Vaccines and Infectious Diseases</orgName>
								<orgName type="institution" key="instit1">Telethon Kids Institute</orgName>
								<orgName type="institution" key="instit2">University of Western Australia</orgName>
								<address>
									<postCode>6009</postCode>
									<settlement>Nedlands</settlement>
									<region>WA</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="laboratory">PathWest Laboratory Medicine</orgName>
								<address>
									<settlement>Perth</settlement>
									<region>WA</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tom</forename><surname>Snelling</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">School of Public Health</orgName>
								<orgName type="institution">University of Sydney</orgName>
								<address>
									<postCode>2006</postCode>
									<settlement>Camperdown</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="laboratory">Wesfarmers Centre of Vaccines and Infectious Diseases</orgName>
								<orgName type="institution" key="instit1">Telethon Kids Institute</orgName>
								<orgName type="institution" key="instit2">University of Western Australia</orgName>
								<address>
									<postCode>6009</postCode>
									<settlement>Nedlands</settlement>
									<region>WA</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">School of Public Health</orgName>
								<orgName type="institution">Curtin University</orgName>
								<address>
									<postCode>6102</postCode>
									<settlement>Bentley</settlement>
									<region>WA</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="institution" key="instit1">Menzies School of Health Research</orgName>
								<orgName type="institution" key="instit2">Charles Darwin University</orgName>
								<address>
									<postCode>0815</postCode>
									<settlement>Darwin</settlement>
									<region>NT</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Ann</forename><forename type="middle">E</forename><surname>Nicholson</surname></persName>
							<email>ann.nicholson@monash.edu</email>
							<affiliation key="aff0">
								<orgName type="department">Faculty of Information Technology</orgName>
								<orgName type="institution">Monash University</orgName>
								<address>
									<postCode>3168</postCode>
									<settlement>Clayton</settlement>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>COVID BN</roleName><forename type="first">Advisory</forename><surname>Group</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Alex</forename><surname>Semprini</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Andrew</forename><surname>Martin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Andrew</forename><surname>Mclean- Tooke</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ben</forename><surname>Marais</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Charlie</forename><surname>Mcleod</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Chris</forename><surname>Lemoh</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Claire</forename><surname>Waddington</surname></persName>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Nolan</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Edward</forename><surname>Raby</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Gladymar</forename><surname>Perez</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Guy</forename><surname>Marks</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Justin</forename><surname>Denholm</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Lisa</forename><surname>Pilgram</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Nicholas</forename><surname>Anstey</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Magdalena</forename><surname>Plebanski</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mark</forename><surname>Boyd</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mina</forename><surname>John</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Paul</forename><surname>Middleton</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Simon</forename><surname>Craig</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Steve</forename><forename type="middle">Y C</forename><surname>Tong</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Susan</forename><surname>Benson</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Toby</forename><surname>Richards</surname></persName>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="department">Department of General Paediatrics</orgName>
								<orgName type="institution" key="instit1">Medical Research Institute of New Zealand, NZ MBBS</orgName>
								<orgName type="institution" key="instit2">BSc (Hons)</orgName>
								<address>
									<region>MInstD</region>
									<country>PhD</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="department">Department of Clinical Immunology</orgName>
								<orgName type="institution" key="instit1">Perth Children&apos;s Hospital</orgName>
								<orgName type="institution" key="instit2">AU University of Western Australia, AU MBBS</orgName>
								<orgName type="institution" key="instit3">FRACP</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Department of Laboratory Immunology</orgName>
								<orgName type="department" key="dep2">PathWest QEII Medical Centre</orgName>
								<orgName type="institution" key="instit1">Sir Charles Gairdner Hospital</orgName>
								<orgName type="institution" key="instit2">AU BSc</orgName>
								<address>
									<addrLine>MBChB</addrLine>
									<region>MD</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff12">
								<orgName type="department">FRCP</orgName>
								<orgName type="institution">University of Sydney Institute for Infectious Diseases, AU MD</orgName>
								<address>
									<addrLine>PhD Benjamin Tang Nepean Hospital</addrLine>
									<region>FRCPath FRCPA</region>
									<country>FRACP</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff13">
								<orgName type="department">FCICM, MBBS</orgName>
								<orgName type="institution">AU Westmead Institute for Medical Research, AU PhD</orgName>
								<address>
									<region>MMed (Clin Epi</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff14">
								<orgName type="department">Infectious Diseases Department</orgName>
								<orgName type="institution" key="instit1">Perth Children&apos;s Hospital</orgName>
								<orgName type="institution" key="instit2">AU Infectious Diseases Implementation Research Team</orgName>
								<orgName type="institution" key="instit3">Telethon Kids Institute</orgName>
								<address>
									<region>AU</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff15">
								<orgName type="department">Christopher Blyth Faculty of Health and Medical Sciences</orgName>
								<orgName type="institution">The University of Western Australia</orgName>
								<address>
									<country>AU</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff16">
								<orgName type="department">Department of Infectious Diseases</orgName>
								<orgName type="institution">Perth Children&apos;s Hospital</orgName>
								<address>
									<country>AU</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff17">
								<orgName type="department">Department of Microbiology</orgName>
								<orgName type="laboratory">Wesfarmers Centre for Vaccines and Infectious Diseases</orgName>
								<orgName type="institution" key="instit1">PathWest Laboratory Medicine WA</orgName>
								<orgName type="institution" key="instit2">QEII Medical Centre</orgName>
								<address>
									<country>AU</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff18">
								<orgName type="department">DCH, FRACP FRCPA</orgName>
								<orgName type="institution" key="instit1">Telethon Kids Institute, AU National Health and Medical Research Council</orgName>
								<orgName type="institution" key="instit2">AU MBBS (Hons)</orgName>
								<address>
									<country>PhD</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff19">
								<orgName type="department" key="dep1">Department of Medicine</orgName>
								<orgName type="department" key="dep2">School of Clinical Sciences at Monash Health</orgName>
								<orgName type="institution">Monash University, AU MBBS</orgName>
								<address>
									<settlement>PhD</settlement>
									<region>FRACP</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff20">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff21">
								<orgName type="department">Department of Immunology</orgName>
								<orgName type="institution">MBBS</orgName>
								<address>
									<country>DPhil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff22">
								<orgName type="department">Department of Infectious Diseases</orgName>
								<orgName type="institution" key="instit1">Royal Perth Hospital</orgName>
								<orgName type="institution" key="instit2">AU MBBS</orgName>
								<orgName type="institution" key="instit3">FRACP</orgName>
								<address>
									<country>PhD</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff23">
								<orgName type="department">Department of Microbiology</orgName>
								<orgName type="institution">Fiona Stanley Hospital</orgName>
								<address>
									<settlement>PathWest</settlement>
									<country>AU</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff24">
								<orgName type="institution" key="instit1">Royal Perth Hospital</orgName>
								<orgName type="institution" key="instit2">AU MBBS</orgName>
								<orgName type="institution" key="instit3">FRACP</orgName>
								<address>
									<region>FRCPA</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff25">
								<orgName type="institution">Curtin University</orgName>
								<address>
									<region>AU</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff26">
								<orgName type="institution">Telethon Kids Institute, AU MD</orgName>
								<address>
									<country>DCTM&amp;H</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff27">
								<orgName type="institution" key="instit1">University of New South Wales Sydney</orgName>
								<orgName type="institution" key="instit2">AU Woolcock Institute of Medical Research, AU BMedSc, MB</orgName>
								<address>
									<region>BS PhD</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff28">
								<orgName type="department">Victorian Infectious Diseases Service</orgName>
								<orgName type="institution" key="instit1">MRCP, FRACP</orgName>
								<orgName type="institution" key="instit2">FAFPHM</orgName>
								<address>
									<region>FAHMS</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff29">
								<orgName type="department">Department of Infectious Diseases</orgName>
								<orgName type="institution" key="instit1">Royal Melbourne Hospital</orgName>
								<orgName type="institution" key="instit2">Melbourne Health</orgName>
								<address>
									<country>AU</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff30">
								<orgName type="department">MBioethics, MPH+TM</orgName>
								<orgName type="institution">University of Melbourne at the Peter Doherty Institute for Infection and Immunity, AU BMed</orgName>
								<address>
									<region>PhD FRACP</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff31">
								<orgName type="department">School of Health and Biomedical Sciences</orgName>
								<orgName type="institution" key="instit1">Menzies School of Health Research</orgName>
								<orgName type="institution" key="instit2">AU Royal Darwin Hospital</orgName>
								<orgName type="institution" key="instit3">AU MBBS (Hons)</orgName>
								<address>
									<settlement>PhD</settlement>
									<region>FRACP</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff32">
								<orgName type="department">Faculty of Health and Medical Sciences</orgName>
								<orgName type="institution" key="instit1">RMIT University, AU BScHon</orgName>
								<orgName type="institution" key="instit2">DPS</orgName>
								<address>
									<region>MBA</region>
									<country>PhD</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff33">
								<orgName type="department" key="dep1">Department, AU Divisions of Emergency Medicine and Paediatrics</orgName>
								<orgName type="department" key="dep2">School of Medicine</orgName>
								<orgName type="department" key="dep3">FRACGP</orgName>
								<orgName type="institution" key="instit1">University of Adelaide</orgName>
								<orgName type="institution" key="instit2">AU MD</orgName>
								<orgName type="institution" key="instit3">FRACP Meredith Borland Perth Children&apos;s Hospital Emergency</orgName>
								<orgName type="institution" key="instit4">University of Western Australia, AU MBBS</orgName>
								<orgName type="institution" key="instit5">FACEM Michael Maze University of Otago</orgName>
								<orgName type="institution" key="instit6">NZ MB</orgName>
								<address>
									<addrLine>ChB</addrLine>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff34">
								<orgName type="department">DCH, DTM&amp;H</orgName>
								<address>
									<region>PhD FRACP</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff35">
								<orgName type="department" key="dep1">Department of Immunology</orgName>
								<orgName type="department" key="dep2">Clinipath Pathology, AU Department of Clinical Immunology</orgName>
								<orgName type="institution" key="instit1">Royal Perth Hospital</orgName>
								<orgName type="institution" key="instit2">AU MBBS</orgName>
								<orgName type="institution" key="instit3">FRACP</orgName>
								<address>
									<region>FRCPA</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff36">
								<orgName type="department">Sydney Clinical School</orgName>
								<orgName type="institution" key="instit1">South Western Emergency Research Institute</orgName>
								<orgName type="institution" key="instit2">Liverpool Hospital</orgName>
								<orgName type="institution" key="instit3">AU South Western</orgName>
								<orgName type="institution" key="instit4">University of New South Wales, AU RGN</orgName>
								<orgName type="institution" key="instit5">MBBS</orgName>
								<address>
									<addrLine>DipIMCRCS (Ed) MMed (Clin Epi), MD (Imp Lond)</addrLine>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff37">
								<orgName type="department">FRCS (Eng)</orgName>
								<address>
									<addrLine>FACPara, FRCEM</addrLine>
									<region>FACEM</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff38">
								<orgName type="department" key="dep1">Department of Paediatrics</orgName>
								<orgName type="department" key="dep2">Department</orgName>
								<orgName type="department" key="dep3">Monash Medical Centre, Emergency Service</orgName>
								<orgName type="department" key="dep4">FACEM</orgName>
								<orgName type="institution" key="instit1">Monash University, AU Paediatric Emergency</orgName>
								<orgName type="institution" key="instit2">Monash Health, AU MBBC</orgName>
								<address>
									<region>MPH MHPE</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff39">
								<orgName type="department" key="dep1">Department of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">AU Victorian Infectious Diseases Service</orgName>
								<orgName type="department" key="dep3">Peter Doherty Institute for Infection and Immunity</orgName>
								<orgName type="institution" key="instit1">The University of Melbourne at the Peter Doherty Institute for Infection and Immunity</orgName>
								<orgName type="institution" key="instit2">The Royal Melbourne Hospital</orgName>
								<orgName type="institution" key="instit3">AU MBBS</orgName>
								<address>
									<country>PhD</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff40">
								<orgName type="department" key="dep1">School of Pathology and Laboratory Medicine</orgName>
								<orgName type="department" key="dep2">FRACP</orgName>
								<orgName type="department" key="dep3">FRCPA, FACHSM</orgName>
								<orgName type="department" key="dep4">DTM&amp;H DipClinEpi</orgName>
								<orgName type="department" key="dep5">Covid Research Response Trial</orgName>
								<orgName type="institution" key="instit1">University of Western Australia</orgName>
								<orgName type="institution" key="instit2">AU School of Population Health</orgName>
								<orgName type="institution" key="instit3">Curtin University, AU MBBS</orgName>
								<orgName type="institution" key="instit4">University of Western Australia</orgName>
								<address>
									<region>AU MD</region>
									<country>FRCS</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Modeling COVID-19 disease processes by remote elicitation of causal Bayesian networks from medical experts</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2022-02-14">February 14, 2022</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.1101/2022.02.14.22270925</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.1" ident="GROBID" when="2025-10-21T20:26+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>COVID-19</term>
					<term>pathophysiology</term>
					<term>Bayesian network</term>
					<term>DAG</term>
					<term>DBN</term>
					<term>causal model</term>
					<term>expert elicitation</term>
					<term>decision support</term>
					<term>experimental design</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p>COVID-19 is a new multi-organ disease, caused by the SARS-CoV-2 virus, resulting in considerable worldwide morbidity and mortality. While many recognized pathophysiological mechanisms are involved, their exact causal relationships remain opaque. A better understanding is needed for predicting their progression, targeting therapeutic approaches, and improving patient outcomes. While many mathematical causal models describe COVID-19 epidemiology, none have been developed for its pathophysiology. The virus's rapid and extensive spread and therapeutic responses made this particularly difficult. Initially, no large patient datasets were publicly available, and their data remains limited. The medical literature was flooded with unfiltered, technical and sometimes conflicting pre-review reports. Clinicians in many countries had little time for academic consultations, and in-person meetings were unsafe.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods and Findings</head><p>In early 2020, we began a major project to develop causal models of the pathophysiological processes underlying the disease's clinical manifestations. We used Bayesian network (BN) models, because they provide both powerful tools for calculation and clear maps of probabilistic causal influence between semantically meaningful variables, as directed acyclic graphs (DAGs). Hence, they can incorporate expert opinion and numerical data, and produce explainable results. Dynamic causal BNs, which represent successive "time slices" of the system, can capture feedback loops and long-term disease progression.</p><p>To obtain the likely causal structures, we used extensive elicitation of expert opinion in structured online sessions. Centered in Australia, with its exceptionally low COVID-19 burden, we managed to obtain many consultation hours. Groups of clinical and other subject matter specialists, all independent volunteers, were enlisted to filter, interpret and discuss the literature and develop a current consensus. We aimed to capture the experts' understanding, so we encouraged discussion and inclusion of theoretically salient latent (i.e., unobservable) variables, documented supporting literature while noting controversies, and allowed experts to propose mechanisms by extrapolation from other diseases. Intermediary experts with some combined expertise facilitated the exchange of knowledge to BN modelers and vice versa. Our method was iterative and incremental: we systematically refined and checked the group output with one-on-one follow-up meetings with the original and new experts to validate previous results. In total, 35 experts contributed 126 face-to-face hours, and could review our products.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p>Our method demonstrates and describes an improved procedure for developing BNs via expert elicitation, which can be implemented rapidly by other teams modeling emergent complex phenomena. The results presented are two key models, for the initial infection of the respiratory tract and the possible progression to complications, as causal DAGs and BNs with corresponding verbal descriptions, dictionaries and sources. These are the first published causal models of COVID-19 pathophysiology, with three anticipated applications: (i) making expert knowledge freely available in a readily understandable and updatable form; (ii) guiding design and analysis of observational and clinical studies, by identifying potential mediators, confounders, and modifiers of treatment effects; (iii) developing and validating parameterized automated tools for causal reasoning and decision support, in clinical and policy settings. We are currently developing such tools for the initial diagnosis, resource management, and prognosis of COVID-19, parameterized using the ISARIC and LEOSS databases.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1">Introduction</head><p>COVID-19 is a new multi-organ disease, caused by the highly infectious SARS-CoV-2 virus, resulting in considerable worldwide morbidity and mortality. While many recognized pathophysiological mechanisms are involved-coagulation and inflammatory cascades, pulmonary exudation and respiratory compensation, endovascular and renal injury-the exact causal relationships between them remain opaque. A better understanding of these causal processes is urgent and important for predicting their progression, targeting therapeutic approaches and improving patient outcomes. To this end, the worldwide pandemic generated a flood of research, but much of the early output was unfiltered, sometimes conflicting, and of reduced reliability <ref type="bibr">[1]</ref>. In contrast, no large patient datasets were publicly available, and even now, their data remains limited.</p><p>In this project, we used online tools to enlist independent medical experts to interpret and iteratively discuss the evolving literature, providing us with consensus views. This process resulted in the elicitation of several detailed graphical causal models of the pathophysiology underlying the clinical manifestations of COVID-19 disease, using the kind of iterative, incremental method widely recommended for model building <ref type="bibr">[2]</ref>, but rarely realized in expert knowledge elicitation. From these theoretical products, simplified models can be constructed for practical application that are parameterized using available data, e.g., for predicting the probability of a patient's future need for intensive care given their current signs, symptoms and laboratory results.</p><p>In this paper, we make freely available our expert-elicited models. While there has been considerable prior work developing causal models of the transmission of SARS-CoV-2 within populations <ref type="bibr">[3]</ref><ref type="bibr">[4]</ref><ref type="bibr">[5]</ref><ref type="bibr">[6]</ref><ref type="bibr">[7]</ref><ref type="bibr">[8]</ref><ref type="bibr">[9]</ref><ref type="bibr">[10]</ref><ref type="bibr">[11]</ref>, ours are the first causal models of the COVID-19 disease process within individuals.</p><p>We anticipate that these models will serve three purposes, for our team and other researchers.</p><p>First, they will aid communication and theoretical understanding, which includes being readily updated to incorporate new findings, and being internally and externally validated using local datasets. Second, they will guide the design and analysis of both observational and clinical studies into COVID-19, by identifying potential mediators, confounders, etc. Third, they will be used to develop and validate parameterized practical tools for causal reasoning and decision support, both in clinical and policy settings.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.1">Causal Bayesian networks</head><p>Bayesian networks (BNs) were designed to model probabilistic causal systems. Formally, a BN <ref type="bibr">[2,</ref><ref type="bibr">12,</ref><ref type="bibr">13]</ref> includes a directed, acyclic graph (DAG), (e.g., Fig. <ref type="figure" target="#fig_0">1</ref>), which consists of nodes connected by arcs (pointing from 'parent' to 'child') that never point in a continuous sequence from a node back to itself. 1 In addition, in a BN each node represents a random variable with multiple possible states, and each arc represents a direct probabilistic dependency, quantified by a conditional probability table (CPT) or equation specifying the probability distribution of the child given the states of all its parents. In causal DAGs and BNs, these arcs also represent direct causal influences-hence they can also predict the effects of decisions regarding interventions. 1 In mathematical graph theory, where early work focused on polyhedra, these are traditionally called 'vertices' connected by 'directed edges'; but common and equivalent terms are 'nodes' connected by 'directed links', 'arrows' or 'arcs'. <ref type="bibr">February</ref>  Alveolar epithelial infection <ref type="bibr">(5)</ref> Viremia <ref type="bibr">(7)</ref> Systemic immune/inflam. response <ref type="bibr">(8)</ref> Pul. capillary leakage <ref type="bibr">(9)</ref> Infection related Infection of olfactory epithelium <ref type="bibr">(3)</ref> Signs and symptoms Alveolar endothelial infection <ref type="bibr">(6)</ref> Dry cough <ref type="bibr">(10)</ref> Productive cough <ref type="bibr">(11)</ref> Anosmia and/or ageusia <ref type="bibr">(4)</ref> Pulmonary related URT = upper respiratory tract pul. = pulmonary inflam. = inflammatory The node Pulmonary capillary leakage, for example, has three 'parents' that jointly influence it, and two 'children' it influences. In the BN, provided in S1 Model, the variable it represents has states and a CPT that are not shown in the DAG. All the nodes are named, numbered, and color coded for ease of reference, and corresponding definitions for variables and arcs are given in the associated Dictionary, S1 Table , an excerpt from which is provided in Fig. <ref type="figure" target="#fig_1">2</ref>.</p><p>Readily available software 2 allows users to enter exact or uncertain evidence about any variables, which is then efficiently propagated to update the probability distributions for all variables. Thus, causal BNs can support and perform prognostic (predictive), diagnostic (retrodictive), explanatory and decision-oriented probabilistic reasoning.</p><p>In a BN, all arcs and nodes-even 'latent' ones, i.e., not directly observable-may be defined in a semantically meaningful way (as in Fig. <ref type="figure" target="#fig_0">1</ref> and Fig. <ref type="figure" target="#fig_1">2</ref>), and this will always be so when the BNs represent knowledge elicited from humans. This transparency is in stark contrast to the opaque "black boxes" of neural networks, where latent nodes are usually connected and pa- One important consequence is that an elicited BN can be readily updated to reflect new human knowledge, which is often derived from more than just a new dataset. Since it is clear which nodes the new knowledge relates to, we can usually identify a few locations where changes are needed while leaving the remainder of the network untouched. This can be extremely useful for complex emergent phenomena, where understanding is advancing rapidly while datasets remain small.</p><p>Another important consequence is that the BN structure and its inferences are potentially explainable, provided that the important aspects of a complicated BN or inference can be identified and clearly articulated. In medicine, for example, for ethical and practical reasons it is better if the recommendations of an AI tool are explainable and justifiable <ref type="bibr">[14,</ref><ref type="bibr">15]</ref>. Algorithms for automatically generating such explanations, which supplement basic BN software by distilling complex inferences into a concentrated essence more palatable for human consumption, are a continuing focus of research, e.g., <ref type="bibr">[15]</ref><ref type="bibr">[16]</ref><ref type="bibr">[17]</ref><ref type="bibr">[18]</ref><ref type="bibr">[19]</ref>. These explanations are often better expressed in causal terms <ref type="bibr">[20]</ref>, including those supporting medical diagnoses <ref type="bibr">[21]</ref>.</p><p>Any causal BN entails a partial time order for its variables: parents precede their children.</p><p>But a BN's capacity to represent time is limited, since cycles are prohibited and each variable usually appears only once, thus making it difficult to represent both feedback loops and time series. A dynamic Bayesian network (DBN) <ref type="bibr">[2]</ref> is a BN in which a variable can be represented multiple times at different discrete time steps, and at any step T it may have parents at </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.2">Building BNs by eliciting expert opinions</head><p>Given a large and representative numerical dataset, preferably supplemented by expert guidance on some causal directions, machine learning algorithms have been developed to find the sparsest causal BNs that could produce the observed dependencies, e.g., PC <ref type="bibr">[13]</ref>, CaMML <ref type="bibr">[22]</ref>,</p><p>and R libraries such as bnlearn (<ref type="url" target="https://www">https://www</ref>. Virus enters upper respiratory tract SARS-CoV-2 infection begins in the upper respiratory tract <ref type="bibr">[1]</ref> causing infection of the epithelial cells in the upper respiratory tract.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>4</head><p>Ageusia and/or anosmia</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Loss of taste and/or smell</head><p>Infection of supporting olfactory epithelium</p><p>The sensation of loss of smell and/or taste occurs due infection of the cells supporting the olfactory neurons, the olfactory epithelial cells <ref type="bibr">[2]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>5</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Alveolar epithelial infection</head><p>Viral tropism of the epithelial cells of the alveoli, inducing an immune response which leads to an altered cellular state (local inflammation).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Virus enters upper respiratory tract, Upper respiratory tract epithelial infection</head><p>The upper airways act as portals for SARS-CoV-2 entry and infection of the alveolar epithelium <ref type="bibr">[4]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="23">Hypoxemia</head><p>Reduced level of oxygen in the blood.</p><p>V/Q mismatch, shunt, Ventilatory insufficiency</p><p>Oxygen levels in the blood are reduced due to inadequate gas exchange and perfusion and/or intrapulmonary shunting due to persistent pulmonary arterial blood flow to non-ventilated alveoli <ref type="bibr">[28]</ref>, <ref type="bibr">[29]</ref> 30</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acidosis</head><p>Decrease in blood pH.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hypercapnia, Hypoxia</head><p>Respiratory acidosis develops due to increased levels of carbon dioxide resulting in an increase in pH <ref type="bibr">[34]</ref>. Hypoxia causes cells to undergo anaerobic metabolism resulting in an increased pH.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>32</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Low oxygen saturation (SaO2)</head><p>Low levels of oxygen in the circulation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hypoxemia</head><p>Hypoxemia can be demonstrated by low oxygen saturation measured by pulse oximetry <ref type="bibr">[28]</ref>.  It is common to use multiple opinions rather than relying on only one source, with the hope of obtaining a larger pool of information and greater reliability from aggregated opinions, and perhaps benefiting from mutual feedback via discussion. Group elicitation of BNs has been particularly popular in some domains, such as reliability assessment <ref type="bibr">[23,</ref><ref type="bibr">24]</ref> and environmental research <ref type="bibr">[25]</ref>.</p><p>When group knowledge is pooled effectively, whether by collation, consensus, averaging, or another form of amalgamation, then it tends to outperform individual knowledge <ref type="bibr">[26]</ref><ref type="bibr">[27]</ref><ref type="bibr">[28]</ref><ref type="bibr">[29]</ref><ref type="bibr">[30]</ref><ref type="bibr">[31]</ref>. However, unstructured group interactions also bring welldocumented problems, e.g., diffusion of responsibility, anchoring, 'groupthink', deference to social status, and unproductive disputes <ref type="bibr">[32]</ref><ref type="bibr">[33]</ref><ref type="bibr">[34]</ref><ref type="bibr">[35]</ref><ref type="bibr">[36]</ref>.</p><p>Such problems can be reduced by using structured protocols, e.g., collecting independent opin- ions from all participants prior to discussion, and also by using a moderator, e.g., to focus discussion on the most pressing issues, encourage only constructive contributions, and help establish a consensus where possible. A BN modeler with appropriate skills may also take the role of the moderator who leads discussion, which is the approach we used.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Software tools have recently been developed</head><p>to support group elicitation of BNs, and the BARD tool <ref type="bibr">[19]</ref> includes multiple options to support highly structured protocols, including a strict version of the widely used Delphi technique <ref type="bibr">[37,</ref><ref type="bibr">38]</ref>. However, we needed to make the elicitation interactions as easy and quick as possible for our experts, so using only a videoconferencing tool (Zoom) with a modeler/facilitator who followed structured but flexible protocols was the most appropriate choice.</p><p>The way BNs are defined in ยง 1.1 might suggest that we build them in the same logical stages, like a waterfall: (i) define all the variables, so that we can (ii) specify all the arcs between them, and then (iii) estimate all the parameters this structure requires. However, for complex BNs this would require uncanny foresight. In contrast, as noted in <ref type="bibr">[19]</ref>, proposed methodolo- Another recommended strategy is to break down complex models into sub-models, and reuse common structures or elements when appropriate, dubbed "idioms" <ref type="bibr">[42]</ref>, "templates" <ref type="bibr">[40]</ref> and "network fragments" <ref type="bibr">[39]</ref>. These incremental approaches adapt similar ideas long used in software engineering, such as "spiral prototyping"</p><p>or "agile model building" <ref type="bibr">[43]</ref>, and reusing common local structures is fundamental to "objectoriented" programming <ref type="bibr">[44]</ref>. An expert modeler/moderator can manage this workflow flexibly and efficiently as issues emerge.</p><p>If probabilities are elicited, then there is usually some degree of uncertainty and disagreement about them. Instead of a single point estimate for each probability, more thorough protocols have been designed to elicit several points (e.g., maximum, minimum, and best estimates) from each of multiple experts and combine this information <ref type="bibr" target="#b53">[45]</ref><ref type="bibr" target="#b54">[46]</ref><ref type="bibr" target="#b55">[47]</ref><ref type="bibr" target="#b56">[48]</ref>. Here, we are concerned principally with causal structure, with probabilities to be determined later from numerical datasets-although frequently experts provide rough indications of influence along with the variables and causal arcs, which can be captured by 'indicative' BN parameters and used for structure validation (see ยง 2.3).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.3">Our contributions</head><p>This paper makes two kinds of novel contributions to prior literature: in method and in results.</p><p>In ยง 2, we demonstrate a structured approach that is only feasible using online tools, which </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2">Methods</head><p>Our elicitation process was organized very quickly, relative to its scale and to similar projects with which any of the present authors have been involved. Organization included our initial planning for which models we wanted to develop, and hence what information we needed to elicit.</p><p>The process was exceptionally intensive, with many experts involved, a high degree of interest, and more detail captured in the expert models than usual. Centered in Australia, with its exceptionally low COVID-19 burden, we managed to obtain a very large number of consultation hours-mostly from experts around Australia, but supplemented by experts overseas.</p><p>Many of these clinical experts therefore had little direct experience in treating COVID-19, with the exception of some overseas recruits with firsthand experience. Nevertheless, since their role was to interpret the available literature in the context of their existing domain knowledge rather than contribute original material, their expertise was adequate for our purposes. Furthermore, in high incidence settings few experts would have had the time to participate.</p><p>There was a high degree of consensus about what was currently established, except when discussing immune processes. However, knowledge in this area was evolving rapidly as new evidence emerged, so as expert opinion was revised we needed to update our models.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1">Social roles for elicitation</head><p>There are three major specialist roles people performed during the elicitation process, which we will refer to as follows: Fourth, the disease involves multiple areas of specialist knowledge, so we would need to elicit opinions from multiple groups of medical experts. Fifth, the logistical challenge of enlisting and managing multiple groups would only be compounded by needing to conduct all meetings online, due to the social effects of the very disease under discussion. Lastly, several models of specific subsystems would need to be synthesized into a single, general master model to provide the theoretical foundation for developing clinical tools. Nevertheless, we took on this difficult challenge. Despite the fact that we did not formally elicit parameters at this stage, after the workshops it was already possible from the discussion, the literature, and our understanding to roughly indicate the expected relationships (e.g., respiratory infection is highly likely to activate the immune system) with 'indicative' BN parameters. These were useful for follow up discussion, and ensured that we specified the states of the variables properly and consolidated our understanding. We also identified some typical clinical scenarios (e.g., common ways the disease progresses).</p><formula xml:id="formula_0">Modelers</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2">Initial models</head><p>We followed up with one-on-one sessions as needed, either with the same experts or supplementary experts with additional expertise. The goals were to clarify and refine the causal structure by discussing it directly, but also to perform a particular kind of validation exercise: checking that the proposed structure with indicative parameters accounted for the typical scenarios.</p><p>We then presented the model to independent experts in one-on-one sessions. The stated goals were the same as the previous sessions, but if the new experts' answers did not substantially differ from those of the previous experts, then this also provided a more thorough form of validation.</p><p>Finally, we sent the refined models to all the participating experts for inspection before  To conduct a group session, we followed a particular elicitation procedure (right column) guiding the introduction, efficient elicitation questions for causal structure, and the kinds of interjections from experts we encouraged. In contrast, for each one-on-one session, a customized agenda was followed with the issues and scenarios to address via more flexible interactions.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4">Procedure around group workshop</head><p>1. Literature review: Coordinators searched for and reviewed relevant articles in the literature. They identified areas of expertise required and some controversial issues. This work continued in parallel to the next two steps. Experts may at any time:  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Expert survey and recruitment</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Workshop scheduling:</head><p>Each week, we collectively decided which workshop to schedule next by reviewing our progress and identifying the most pressing need. We invited suitable experts with limited notice (2 weeks) but achieved good participation rates, which we attribute to a strong motivation to contribute to the pandemic response as well as, in some cases, existing relationships with our team. Since not everyone who was willing to contribute could be available at any given time, we invited more people than we could optimally accommodate, and anyone who could not attend was invited to validate the model in a subsequent round. We scheduled 2 h timeslots, since in our experience this is the minimum to introduce experts to the technology and to the problem and still have adequate time to elicit their opinions. This is also the maximum time that most of our experts could contribute (due to limited time or attention), and most indicated a preference for shorter sessions. We tried to run the sessions as efficiently as possible, but used the full 2 h in every case.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Pre-workshop preparation:</head><p>Prior to each workshop, we gave participants background material that identified issues and summarized features of the model to be discussed and developed during the workshop. We used the literature review to prepare a starting template for the model. This gave our experts something to critique and expand upon, rather than starting from a blank slate, and hence expedited discussion and elicitation. We also presented a schematic overview of how each submodel would fit in with the others, and an explanation of the goals of our project.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">Elicitation workshop:</head><p>We began each workshop with a short presentation that in- the "raw data" of these elicitation sessions, have been retained and securely stored. We used our newfound understanding to choose and sched-ule subsequent elicitations and actions. These included emailing questions to specific experts that were present or to other experts with different skill sets or knowledge, and then if needed, scheduling one-on-one elicitation sessions.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.">Translation to application models:</head><p>As a result of our various expert elicitation sessions, we produced multiple "expert models" that represented different body subsystems, and sometimes represented alternative perspectives put forward by different experts. Our approach here was exploratory, avoiding premature judgments on what would be important for practical applications, so we tried to capture this theoretical expert knowledge comprehensively. However, our ultimate aim is to develop practical tools powered by customized "application models", the first of which will be to support clinical reasoning in the prognostication for COVID-19.</p><p>The expert models will provide a theoretical rationale for, and increase confidence in, the validity of the application models. Our modelers decide which aspects of the expert models are most relevant and should be included in an application model, given its purpose and required outcomes. In some respects an application model may be simplified, e.g., by combining several latent variables. In other respects, it may be more sophisticated, e.g., by creating a DBN representing the whole system based on multiple expert BNs representing subsystems. The application models we have already developed are currently being independently validated by experts, both structurally and quantitatively, as well as validated by their fit to the data.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.5">Adaptive, spiral processes</head><p>Although we depict our methods as several linear sequences, our description should make clear February 14, 2022 14/32</p><p>Modeling COVID-19 disease processes by eliciting causal BNs Mascaro et al.</p><p>that in combination these formed a spiral process, as widely recommended for model building:</p><p>i.e., our sequences of steps were iterated to produce successive improvement. Most obviously, the sequence depicted in Fig. <ref type="figure">3</ref> is designed to successively refine and validate elements of the model through repeated elicitation.</p><p>In the same vein, we also used an adaptive elicitation procedure, i.e., we used the outcomes of elicitation and modeling exercises to help decide what sort of elicitation and modeling should be done next. So, to some extent, we learned and refined our methods over the course of the project.</p><p>One example of adaptive elicitation was modifying our pre-workshop material for participants. For our early workshops, we prepared surveys on issues where we identified disagreement in the literature. We aimed to engage and prepare participants, and obtain a preliminary understanding of their views. However, despite the assistance of our coordinators, we found it difficult to design survey questions that our modelers felt were relevant to the modeling choices, yet were framed and expressed in a way that most medical experts felt they could respond to.</p><p>For example, experts often felt the answers were dependent on unstated contextual details.</p><p>For subsequent workshops, we simply gave participants background material that identified such issues of disagreement, and summarized features of the model to be discussed and developed during the workshop. In our video conferences, where elicitation and model building were more coordinated and interactive, we found that modelers and medical experts had much less difficulty in translating medical knowledge to models and vice versa.</p><p>Another example of adaptive elicitation was adding post-workshop supplementary meetings.</p><p>After holding 2 h elicitation workshops with groups of medical experts to generate a consensus BN, it became clear that follow-up oneon-one meetings would be useful, with some of the workshop participants and sometimes with other experts who had different expertise. These meetings allowed experts who wanted additional time to give more detailed feedback on the model, and they were also a better forum for resolving persistent points of disagreement or uncertainty.</p><p>3 Results and Discussion We detail these procedural missteps and 'dead-ends' to accurately describe a method of modeling, whereas omitting or rewriting this history might give the misleading impression that the two models presented below were always exactly the intended output.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2">Method of presentation</head><p>Since COVID-19 pathophysiology is complex, we developed several BNs for different subsystems;</p><p>here we present our two main products. Our Respiratory BN concerns the detailed pathways that link the initiating infection to respiratory pathophysiology and the beginning of complications, and hence it focuses primarily on the lungs. Our</p><p>Complications BN concerns higher-level interactions and how the disease may progress after complications have begun, and hence it includes other organs that become important later in the progression of a severe case.</p><p>We present the models in three complementary types of file: 2. BN descriptions and issues, which summarize the processes these graphs represent ( ยง 3.4 and 3.6), and discuss a few unusual or controversial features ( ยง 3.5 and 3.7).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">BN dictionaries with references, which</head><p>give the definitions of variables and states, and also cite some of the research literature that supported specific BN features. We present illustrative examples in Fig. <ref type="figure" target="#fig_1">2</ref>, discuss some general features in ยง 3.8, and provide the complete documents as supplementary files (S1 Table , 

S2 Table ).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3">Limitations of our models</head><p>While there are still unknowns and competing hypotheses in the literature, the differences are  Structurally, they can be appended as additional effects of some of the variables in our DAGs, without changing the existing DAG connections.</p><p>As data becomes available (e.g., the false positive and false negative rates for a new test) then their CPT parameters can be estimated.</p><p>Feedback loops, i.e., variables that influence each other over time, are not included in these acyclic models. Some are, however, noted in the BN dictionary. Feedback loops, like background variables, are explicitly included in our parameterized Progression DBN for modeling longer-term COVID-19 trajectories. The details will be presented in a future publication on this model and associated practical tools. 3 We implemented this procedure in the subsequent development of our parameterized Progression DBN. We conducted a survey and group elicitation session dedicated to background factors, where we asked experts which of the Progression variables (which do not include all the theoretical variables here) would be affected.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4">Respiratory BN Description</head><p>Our which interacts with the rest of the system in a complicated way that is not explicitly described here, but which can lead to Impaired cardiac output.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Complications</head><p>The </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5">Respiratory BN Issues</head><p>We describe here four issues with our Respiratory </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Neurological explanation for "happy hy-</head><p>poxics": We model the patient's perceived need for air separately from dyspnea (shortness of breath). An unusual feature of COVID has been patients who present as "happy hypoxics" (physiologically hypoxic but without symptoms) <ref type="bibr" target="#b59">[51]</ref>.</p><p>One causal hypothesis is that neurological viral infection inhibits the perceived need for air.</p><p>However, at the time of modeling this connection was very speculative, so we decided not to include this pathway, pending further medical research.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.6">Complications BN description</head><p>Our Complications causal DAG (S2 Fig. The hypercoagulable state may increase the vascular resistance to flow of blood through affected vessels. Abnormally low vascular resistance is also problematic because it can lead to insufficient pressures needed to ensure the distribution of blood and perfusion of the organs.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cardiac system incl. Vascular interaction</head><p>The </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Other organ dysfunctions and failures</head><p>The ultimate need of organs is enough oxygen and metabolites supplied through the blood circulation to maintain their vital functions, we February 14, 2022 22/32</p><p>Modeling COVID-19 disease processes by eliciting causal BNs Mascaro et al.</p><p>have therefore replaced Hypoxia from the Respiratory model with separate nodes that distinguish between the supply of blood (as organ perfusion) and the supply of oxygen and metabolites.</p><p>Reduced supply of blood will lead to reduced supply of oxygen and metabolites, and the latter will also be reduced if there is a lack of oxygen in blood (hypoxemia) even if the supply of blood is normal.</p><p>Reduced supply of oxygen and metabolites can lead to dysfunction of any of the listed endorgans, which often further disrupts the balance of the whole system. For example, liver, kidney and gut play important roles in maintaining the balance of electrolytes, metabolites and acids.</p><p>The dysfunction of these organs would generate feedback loops with other organs including pulmonary, cardiac, and vascular systems via electrolyte and metabolite imbalance and acidosis.</p><p>In this model, we summarize all such feedback loops by presenting only their final deterioration to particular organ failures.</p><p>Since vascular failure is ill defined, we instead represent a key pathway in which a hypercoagulable state combined with possible liver, kidney and hematologic dysfunctions lead to general coagulopathy that can in turn contribute to severe vascular dysfunction that may result in the heart stopping and subsequent death. Critical failures of the brainstem, pulmonary, and cardiac systems also rapidly lead to an inability to support any of the vital organ functions and are terminal events.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.7">Complications BN issues</head><p>As </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Lung-acidosis feedback loop:</head><p>The Complications model involves several important feedback loops. For example, as noted in the description, if the lungs are damaged and do not adequately remove CO 2 , then the resulting acidosis may damage the lungs themselves.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.8">BN Dictionaries with References</head><p>All variables in these two BNs have both descriptions and their relationships with their parent nodes (supported by selected references) specified in their Dictionaries (S1 Table, S2 Table ); a few illustrative examples are given in Fig. <ref type="figure" target="#fig_1">2</ref>.</p><p>Here we discuss some general features.</p><p>Definitions and databases: Chronic pulmonary disease in Fig. <ref type="figure" target="#fig_1">2</ref>  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4">Conclusion</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1">Value of our method</head><p>Methodologically, we have demonstrated how to implement best practice recommendations in a systematic, expanded procedure for developing BNs via expert elicitation. This can be emulated, adapted and refined in future projects. It is particularly well suited to projects modeling emergent diseases, since (i) it uses large-scale online expert elicitation to develop causal structure, rather than only using data or literature directly, and (ii) it produces a family of welldocumented theoretical models that make the expert knowledge freely available and that can be updated as the knowledge base develops, rather than only producing a few practical BN tools that can be derived from, and supported by, the hidden theoretical base.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Harnesses worldwide expertise when data and literature are lacking</head><p>We demonstrated how to overcome the scarcity of data, and the exceptional abundance and unreliability of research literature, by using groups of volunteer, independent, specialist domain experts to filter, interpret and discuss the literature findings and develop a reasonable current consensus. We also utilized intermediary experts to facilitate the exchange of knowledge from domain specialists to BN modelers and vice versa.</p><p>This approach is unusual, and the total number of expert hours required was exceptionally high. We obtained these hours by recruiting a large number of experts to contribute the time they could spare, which was facilitated by our extensive use of online meetings. In addition to being COVID-safe, they had the logistical advantages that experts could meet briefly within their busy schedules from their normal places of work and in highly dispersed locations, without the overhead of travel time or even needing to be in the same country, which effectively broadened our pool of available experts and the number of elicitation sessions which were feasible. Online tools also enabled all our elicitation exchanges to be easily recorded. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adaptive evolution of theoretical models that can be updated and used by others</head><p>We followed an unusual two-phase process of BN development and publication. We aimed to first elicit relatively detailed causal models that captured the experts' understanding of the relevant processes, including theoretically salient latent variables that might not be useful in the specific, practical BN tools we aimed to subsequently develop. Furthermore, we are publishing here the full details of, and documentation for, these causal models. The goal is to make the elicited expert knowledge freely available to others in a form that can be readily updated as medical science progresses, and used for a variety of purposes.</p><p>Since both the method and domain were large, complex and novel, it was necessary to subdivide, adapt and evolve both the elicitation procedure and the models. We developed a systematic approach of refining and checking the group output with one-on-one follow-up meetings as necessary, with both group members and new, independent recruits. By enlisting new domain experts, we progressively validated and refined our models in the iterative, incremental style that is broadly recommended for BN building, but is more logistically challenging and has rarely been achieved when using expert elicitation.</p><p>Although we have specified our method in clear logical sequences, we stress that in model building, teams need to be flexible and in some respects progress is unpredictable. Pre-workshop questionnaires, which we abandoned, may prove more suited to other topics, especially where variables are known or easily identified beforehand; an elicitation workshop may reveal that substantial supplementary expertise or literature is required; it may become clear that models should be split or merged; and even after experts have signed off on a model it may need to be abandoned if subsequent testing with numerical datasets doesn't support it.</p><p>There is also scope to refine our methods further and test some variations in future applications. For example, group workshops followed by one-on-one follow ups worked well, bringing key information and model structures together quickly (via the workshops) and then allowing more cautious validation and refinement of those structures in detail (via the follow ups). However, we now believe that conducting some oneon-one interviews may be useful earlier in the elicitation process. They may be useful prior to questionnaires to increase the chance that questions handle problematic concepts well, or prior to group workshops to provide better structure for those sessions. Medical science is constantly progressing, so our models must be refined accordingly-possibly using the method we have provided here, whether employed by us or by others.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2">Value of our models</head><p>Fortunately, most of our work will not need to be repeated, since elicited causal DAGs can be readily updated ( ยง 1.1 Feedback loops are not incorporated in these DAGs, even though some are important for modeling the progression of the disease over longer time scales. We noted some of these loops in the Dictionaries, and will discuss them in future work, in conjunction with presenting our DBN model for disease progression.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Guiding design of empirical studies</head><p>Causal DAGs are now widely recommended to inform the design and analysis of health-related observational studies <ref type="bibr" target="#b61">[53]</ref>. Causal DAGs have similar applications to the design of experimental studies, even where manipulation or randomization of the treatment variables reduces confounding. So, we anticipate that our models will also be useful to guide the design of clinical trials of treatments for SARS-CoV-2 infection.</p><p>Our DAGs can be used to identify important non-treatment factors that may influence and produce unwanted variation in the trial outcome, and which should therefore be considered for control by stratification or statistical adjustment (regardless of whether treatment randomization is employed) in order to increase the statistical power of the experiment. Similarly, our DAGs can be used to identify factors that might modify the effect of treatments, which should therefore be used to pre-specify patient subgroups.</p><p>By quantifying the pathways in our models that connect proximal outcomes such as hypoxia or biomarkers to key outcomes of interest such as the need for mechanical ventilation or death, it may be possible to design more statistically efficient trials that use the former as plausible surrogate endpoints for the latter. For example, we may use the degree to which a treatment reduces hypoxia and specific biomarkers in a larger group of patients as a more statistically powerful way of quantifying the expected reduction in the need for mechanical ventilation, which eventually occurs in a smaller subset of patients.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Developing and validating practical tools</head><p>Our models will be useful in the development and/or validation of fully parameterized practical tools for causal reasoning and decision support. In addition to using them for individual decision-making in a clinical setting, such tools can also be used as an aid to policy decisionmaking at a broader level, for example, by considering risks that apply to whole populations, or the effect of non-targeted interventions applied to readily identifiable patient subgroups.</p><p>Practical tools can be developed by any researchers directly from our models, or from future updated versions of them. This often involves identifying which evidence (observable) variables are included in the available datasets that will be used for parameterization. The theoretical causal structure of our DAGs can then be simplified or adapted to omit or merge some latent variables, while trying to retain sufficient latent structure to encode the expected eviden-February 14, 2022 27/32</p><p>Modeling COVID-19 disease processes by eliciting causal BNs Mascaro et al.</p><p>tial dependencies. These application models are then parameterized using the datasets, and may be further modified depending upon their performance (e.g., using cross validation to assess their mean predictive accuracy on various measures for target variables given some evidence). Even if an application model is developed independently of our models, the dependencies this application model encodes between variables (including interventions) can be checked against our DAGs to identify any likely discrepancies.</p><p>Our models thus provide a ready-made and well grounded source of theoretical validation for other research teams using different modeling methods.</p><p>In our ongoing work with these BN models, we are already developing several of our own tools for either standalone or integrated decision support, parameterized using the IDDO subset of the ISARIC database (<ref type="url" target="https://www.iddo">https://www.iddo</ref>.</p><p>org/covid-19) and LEOSS databases (https:</p><p>//leoss.net/). We are tailoring two distinct tools based on an applied version of the models we have described here, one for in-hospital prog- </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supporting information</head><p>All the following supplementary files will remain available on our OSF project page (https:// osf.io/bynr6/) in the versions referred to here, accompanied by any subsequent versions of them that we develop.  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>S1</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>3</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Infection of olfactory epithelium</head><p>Viral tropism of the olfactory epithelial cells, leading to impaired function</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Upper respiratory tract epithelial infection</head><p>SARS-CoV-2 travels up the upper respiratory tract infecting the olfactory epithelium entering via the ACE2 receptors <ref type="bibr">[2]</ref>, <ref type="bibr">[3]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>4</head><p>Ageusia and/or anosmia</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Loss of taste and/or smell</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Infection of supporting olfactory epithelium</head><p>The sensation of loss of smell and/or taste occurs due infection of the cells supporting the olfactory neurons, the olfactory epithelial cells <ref type="bibr">[2]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>5</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Alveolar epithelial infection</head><p>Viral tropism of the epithelial cells of the alveoli, inducing an immune response which leads to an altered cellular state (local inflammation).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Virus enters upper respiratory tract, Upper respiratory tract epithelial infection</head><p>The upper airways act as portals for SARS-CoV-2 entry and infection of the alveolar epithelium <ref type="bibr">[4]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>6</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Alveolar endothelial infection</head><p>Viral tropism of the endothelial cells of the alveoli, inducing an immune response which causes to an altered cellular state (local inflammation).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Alveolar epithelial infection</head><p>SARS-CoV-2 transverse the alveolar epithelium to infect the alveolar endothelium <ref type="bibr">[5]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7">Viremia</head><p>Presence of SARS-CoV-2 in plasma allowing for systemic distribution of the virus.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Upper respiratory tract epithelial infection, Alveolar epithelial infection, Alveolar endothelial infection</head><p>In COVID-19, the barrier between the upper respiratory tract (upper respiratory tract epithelium, alveolar epithelium) and circulatory system (alveolar endothelium) may be compromised causing leakage of the virus into the blood <ref type="bibr">[6]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>8</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Systemic immune/ inflammatory (inflam.) response</head><p>Activation of the innate and adaptive immune system due to detection of viral particles at one or more body site/s. This often results in the release of pro-and/or anti-inflammatory markers in blood by immune-related cells.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Upper respiratory tract epithelial infection, Alveolar epithelial infection, Alveolar endothelial infection, Viremia</head><p>Infection of the alveolar epithelial cells <ref type="bibr">[7]</ref>, alveolar endothelial cells <ref type="bibr">[8]</ref>, <ref type="bibr">[9]</ref>, the presence of viral material in the blood <ref type="bibr">[10]</ref> simulate a systemic inflammatory immune response including the migration of inflammatory cells to the infected site and the release of cytokines and chemokines.</p><p>2/5</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ID Variable name Description Parent nodes</head><p>Relationships with parent nodes 9</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pulmonary capillary leakage</head><p>Leakage of the plasma into the tissues from the pulmonary capillaries.</p><p>Alveolar epithelial infection, Alveolar endothelial infection, Systemic immune/ inflam. response</p><p>Infection of the alveolar units including the endothelial cells <ref type="bibr">[5]</ref> and associated immune response <ref type="bibr">[11]</ref>, <ref type="bibr">[12]</ref> damage cells resulting in increased vascular permeability and leakage of plasma into the tissues.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="10">Dry cough</head><p>A reflex action intended to clear the airways due to irritation without the production of mucus or phlegm.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pulmonary capillary leakage, Upper respiratory tract epithelial infection</head><p>The upper respiratory tract irritation can cause dry cough. Inflammation and irritation of the lower respiratory tract can also trigger cough. <ref type="bibr">[13]</ref> 11 Productive cough A reflex action intended to clear the airways due to irritation secondary to the production of mucus or phlegm.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Alveolar epithelial infection, Pulmonary capillary leakage</head><p>Productive cough is usually caused by the presence of secretion in the lower respiratory tract. <ref type="bibr">[13]</ref>, <ref type="bibr">[14]</ref> 12</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Alveolar consolidation</head><p>Alveolar airspaces become filled with liquid, cells, tissues and other materials.</p><p>Alveolar epithelial infection, Pulmonary capillary leakage.</p><p>Plasma leaks from the capillaries and cells migrate to the alveolar airspaces in response to infection of the epithelial cells and increased permeability of the capillaries. Cell death further simulate the infiltration of inflammatory cells and a protein-rich exudate within the alveolar space <ref type="bibr">[15]</ref>, <ref type="bibr">[16]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>13</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reduced lung compliance</head><p>Reduced expansion (change in volume) of the lungs per unit increase in the transpulmonary pressure (at equilibrium).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Alveolar consolidation, Alveolar epithelial infection</head><p>Infection of type II pneumocytes of the alveolar epithelium reduces surfactant secretion causing atelectasis of the lungs which, along with alveolar consolidation, reduces lung compliance <ref type="bibr">[15]</ref> 14</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Muscle wasting</head><p>Loss of respiratory skeletal muscle over time resulting in a functional respiratory impairment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Systemic immune/inflam. response</head><p>Systemic inflammation and hypoxia (feedback loop not shown) drives muscle catabolism and decreases muscle protein synthesis that then causes muscle wasting and reduced mechanical capacity of the lungs <ref type="bibr">[17]</ref>. The loss of skeletal muscle mass can also be caused by immobility, aging, malnutrition, medications (not shown in this model).</p><p>Note that this a slower process that occur over weeks rather than days (compared with some other events described in the model).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>15</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ventilatory insufficiency</head><p>The collective chemical and mechanical factors preventing the adequate receipt of oxygen and elimination of carbon dioxide.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reduced lung compliance, Muscle wasting</head><p>When alveolar consolidation reaches a certain magnitude, there is a decrease gas volume in the lungs (reduced compliance), and tidal volumes produced for a given inspiratory pressure preventing the exchange of oxygen and carbon dioxide <ref type="bibr">[18]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>16</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pulmonary vasoconstriction</head><p>Constriction of the vascular smooth muscles in response to low levels of alveolar oxygen or molecular promotors resulting in increased vascular resistance.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Alveolar epithelial infection, Alveolar endothelial infection</head><p>Alveolar epithelial and endothelial infection lead to local hypoxia (feedback loop not shown) that can cause vasoconstriction. Disruption in the Renin-Angiotensin System associated with endothelial infection via ACE2 receptors reduces expression of ACE2, which results in an increase of a number of molecules that promote pulmonary vasoconstriction <ref type="bibr">[19]</ref>. Presence of viral material in the blood <ref type="bibr">[10]</ref>, infection of endothelial cells <ref type="bibr">[20]</ref> and the systemic immune/inflammatory response <ref type="bibr">[21]</ref> activate the coagulation cascade (thrombin/ coagulation proteases, fibrinogen and platelets) inducing a hypercoagulable state as a physiological effort to repair damaged blood vessels and limit viral replication <ref type="bibr">[22]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>18</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pulmonary microthrombosis</head><p>Small fragments of coagulated blood in the pulmonary circulation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hypercoagulable state</head><p>Coagulation is initiated as a result of the hypercoagulable state and pulmonary endothelial injury resulting in disruption of the cell membrane manifesting a pulmonary microthrombi <ref type="bibr">[23]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>19</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pulmonary circulatory blockage</head><p>Blockage of pulmonary circulation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Alveolar endothelial infection, Pulmonary microthrombosis, Other thrombosis</head><p>The formation of multiple microthrombi and/or larger thrombi cause emboli in the pulmonary arteries <ref type="bibr">[24]</ref>. Alveolar inflammation and blood clots can lead to blockage of pulmonary circulation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>20</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pulmonary hypertension</head><p>High blood pressure in the pulmonary arteries.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pulmonary circulatory blockage, Pulmonary vasoconstriction, Hypoxemia</head><p>Vascular manifestations such as pulmonary and other thrombosis and sustained pulmonary vasoconstriction (which can be caused by hypoxemia) result in pulmonary hypertension due to persistently high blood pressure <ref type="bibr">[21]</ref>, <ref type="bibr">[25]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="21">V/Q mismatch</head><p>A state of ventilation and perfusion whereby the gas exchange is inadequate to meet the needs to oxygen delivery and carbon dioxide removal.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pulmonary circulatory blockage, Pulmonary vasoconstriction, Pulmonary capillary leakage, Alveolar consolidation</head><p>V/Q mismatch can be a result of obstruction of circulation in the pulmonary arteries due to pulmonary embolism impedes blood flow and gas exchange <ref type="bibr">[26]</ref>, <ref type="bibr">[27]</ref>. Consolidation of the alveolar sacs due to inflammation and alveolar capillary leak reducing surface area for gas exchange <ref type="bibr">[28]</ref>. Vasoconstriction helps to match regional perfusion to ventilation in the lungs. The failure of the hypoxic pulmonary vasoconstriction mechanism leads to persistent high pulmonary blood flow of poorly ventilated alveoli <ref type="bibr">[29]</ref> which allows for carbon dioxide to be removed at a greater rate than the receipt of oxygen.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="22">Shunt</head><p>An extreme state of V/Q mismatch where blood is shunted away from the functioning lung tissues.</p><p>Pulmonary capillary leakage, Alveolar consolidation, V/Q mismatch Failure of pulmonary vasoconstriction allows for perfusion of blood to areas with inadequate ventilation due to a pulmonary capillary leakage and consolidation, worsening V/Q mismatch <ref type="bibr">[30]</ref> 23 Hypoxemia</p><p>Reduced level of oxygen in the blood.</p><p>V/Q mismatch, Shunt, Ventilatory insufficiency</p><p>Oxygen levels in the blood are reduced due to inadequate gas exchange and perfusion and/or intrapulmonary shunting due to persistent pulmonary arterial blood flow to non-ventilated alveoli <ref type="bibr">[28]</ref>, <ref type="bibr">[29]</ref> 24 Hypercapnia</p><p>Increased level of carbon dioxide in the blood.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>V/Q mismatch, Ventilatory insufficiency</head><p>Carbon dioxide abnormally accumulates in the blood due to insufficient ventilation and inadequate gas exchange <ref type="bibr">[28]</ref>, <ref type="bibr">[29]</ref>.</p><p>4/5</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ID Variable name</head><note type="other">Description Parent nodes Relationships with parent nodes 25</note></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Perceived need for air</head><p>Sensation of need and potential need of more oxygen.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reduced lung compliance, Hypoxemia, Hypercapnia, Acidosis</head><p>Sensation of insufficient respiration (oxygen) is detected due to low oxygen levels, high carbon dioxide levels and a low pH by peripheral and central chemoreceptors. Mechanostretch receptors in the muscles and lungs also provide sensory feedback as a result of reduced compliance and respiratory muscle weakness due to altered lung mechanics <ref type="bibr">[29]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="26">Other thrombosis</head><p>Large thromboses including pulmonary arterial thrombosis and venous thrombosis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hypercoagulable state</head><p>Large clots are thrombotic complications resulting from a hypercoagulable state <ref type="bibr">[31]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>27</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abnormal contractility</head><p>In model, refers to abnormal cardiac electrophysiology, resulting in an alteration in the rate and/or coordination of contractility.</p><p>Systemic immune/inflam. response, Hypoxemia</p><p>An hypoxic state and the immune and inflammatory response such as cytokine storm due to infection with COVID-19 can result in reduced function of the myocardial cells <ref type="bibr">[21]</ref>, <ref type="bibr">[32]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>28</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reduced cardiac output</head><p>A reduction in the amount of blood the heart pumps per unit time.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abnormal contractility, Other thrombosis, Pulmonary hypertension</head><p>Cardiac output is a function of heart rate and stroke volume.</p><p>Thrombosis can lead to reducing stroke volume by blocking blood flow, it may also trigger acute cardiac injury thus reduce contractility. Diminished myocardial contractility reduces the heart rate <ref type="bibr">[21]</ref>, <ref type="bibr">[28]</ref> Pulmonary hypertension can impair cardiac output by making it hard for the heart to pump out blood due to increased vascular resistance and pulmonary pressures <ref type="bibr">[33]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="29">Hypoxia</head><p>Reduced level of tissue oxygenation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hypoxemia, Reduced cardiac output</head><p>Low levels of oxygen in the blood and reduced blood flow prevents adequate oxygen delivery to the tissues <ref type="bibr">[28]</ref> 30</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acidosis</head><p>Decrease in blood pH.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hypercapnia, Hypoxia</head><p>Respiratory acidosis develops due to increased levels of carbon dioxide resulting in an increase in pH <ref type="bibr">[34]</ref>. Hypoxia causes cells to undergo anaerobic metabolism resulting in an increased pH.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="31">Multiorgan failure</head><p>Altered function of two or more organ systems and failure to maintain homeostasis.</p><p>Hypoxia, Acidosis, Other thrombosis, Viremia, Systemic immune/inflam. response, Reduced cardiac output Systemic inflammatory response and viremia can impair organ function via cell damage. Hypoxia results in cell death and subsequent organ failure <ref type="bibr">[35]</ref>. Acidosis causes significant disruption in homeostasis <ref type="bibr">[28]</ref>. Both hypoxia and acidosis can be caused by reduced blood flow to organs due to impaired cardiac output and thrombosis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>32</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Low oxygen saturation (SaO2)</head><p>Low levels of oxygen in the circulation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hypoxemia</head><p>Hypoxemia can be demonstrated by low oxygen saturation measured by pulse oximetry <ref type="bibr">[28]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="33">Dyspnea</head><p>A subjective experience of breathing discomfort (shortness of breath).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Perceived need for air</head><p>Dyspnea occurs when an individual responds to the sensation of need for oxygen (e.g., hypoxemia) <ref type="bibr">[29]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="34">Death</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mortality due to COVID-19</head><p>Multi-organ failure Multi-organ failure directly causes of death due to COVID-19 <ref type="bibr">[36]</ref>. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Respiratory infection</head><p>Viral replication stimulates systemic immune and inflammatory response <ref type="bibr">[2]</ref>, <ref type="bibr">[3]</ref>, <ref type="bibr">[8]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>12</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Direct viral injury</head><p>Injury to the cells caused by direct effects of viral infection.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Respiratory infection, Upregulation of ACE2 receptors</head><p>Larger quantities of virus cause more direct damage to cells. Upregulation of ACE2 receptors facilitates viral entry into cells, contributing to more direct viral injury <ref type="bibr">[9]</ref>, <ref type="bibr">[10]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13">Hypoxemia</head><p>Reduced levels of oxygen in blood.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pulmonary dysfunction</head><p>Insufficient gas exchange can reduce blood oxygen levels <ref type="bibr">[11]</ref>, <ref type="bibr">[12]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="14">Hypercapnia</head><p>Increased carbon dioxide levels in blood.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pulmonary dysfunction</head><p>Insufficient gas exchange can lead to accumulation of carbon dioxide in blood <ref type="bibr">[11]</ref>, <ref type="bibr">[12]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>15</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hyperdynamic circulation</head><p>Increased cardiac output above baseline to maintain tissue perfusion, in response to inappropriately low peripheral vascular tone.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reduced vascular tone</head><p>Hyperdynamic circulation can be triggered in response to inappropriately low peripheral vascular tone <ref type="bibr">[13]</ref>.</p><p>16</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fluid shift to interstitium</head><p>Fluid moves from the intravascular space (blood vessels) into the interstitial or "third" space.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reduced vascular integrity</head><p>Loss of integrity increases the permeability of the vascular endothelial junction, allowing more fluid to shift into this space <ref type="bibr">[14]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="17">Dehydration</head><p>Refers to a deficiency in total body water.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Systemic immune/inflam. response</head><p>Fever, generated as part of the systemic response, increase water losses <ref type="bibr">[15]</ref>. Organ perfusion has multiple definitions.</p><p>In this model, it refers to the blood flow level to perfuse (end) organs such as the kidneys and brain.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hypercoagulable state, Reduced cardiac output, Vascular resistance</head><p>Insufficient organ perfusion can be caused by not enough blood being pumped out by heart (reduced cardiac output), and thrombosis (hypercoagulable state) <ref type="bibr">[14]</ref>. Decrease in vascular resistance causes reduced organ perfusion <ref type="bibr">[16]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>20</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reduced supply of oxygen and metabolites</head><p>The reduced supply of oxygen and metabolites to meet the organ needs.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reduced organ perfusion (supply of blood), Hypoxemia</head><p>Decreased perfusion reduces the amount of blood and the associated oxygen and metabolites delivered to an organ. Insufficient oxygen to meet the organ needs if there is lack of oxygen in blood (hypoxemia) regardless of blood supply. 26 Death</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cessation biological functions</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Heart stops</head><p>Cessation of perfusion of organs contributing cell dysfunction and death.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>27</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reduced vascular integrity</head><p>Alterations in endothelial cell viability, structure and function, compromising permeability.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Systemic immune/inflam. response, Direct viral injury</head><p>Direct viral injury can damage and kill endothelial cells. The systemic immune response can cause similar damage when responding to infection <ref type="bibr">[14]</ref>.</p><p>4/8 Infection of endothelial cells and the systemic immune/inflammatory response activate the coagulation cascade (thrombin/ coagulation proteases, fibrinogen and platelets) inducing a hypercoagulable state as a physiological effort to repair damaged blood vessels and limit viral replication <ref type="bibr">[4]</ref>, <ref type="bibr">[23]</ref>- <ref type="bibr">[25]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>29</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reduced vascular tone</head><p>Decrease in the degree of constriction of a blood vessel.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Systemic immune response, Direct viral injury, Hypercapnia, Hypoxemia</head><p>Endothelial cell death and dysfunction and chemical signals generated as part of the systemic response contribute to the dysregulation of tone <ref type="bibr">[2]</ref>. Blood vessels are sensitive to changes in pCO2, the low pH values (hypercapnia) lead to relaxation of vascular smooth muscle <ref type="bibr">[26]</ref>, <ref type="bibr">[27]</ref>. Hypoxemia disrupts the control of vascular tone <ref type="bibr">[28]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>30</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Vascular resistance</head><p>Refers to increase or decrease of the resistance of vessel wall.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reduced vascular tone, Reduced functional intravascular volume, Hypercoagulable state</head><p>Tone and vascular resistance can increase in response to reduced functional volume to maintain perfusion. Thrombosis can result in increased resistance by vessels and restricting downstream flow.</p><p>[14]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="31">Coagulopathy</head><p>Derangement of the balance of the coagulation cascade resulting in increased blood clotting, bleeding or a combination of both.</p><p>Liver dysfunction, Marrow dysfunction, Kidney dysfunction, Hypercoagulable state</p><p>The liver and bone marrow produce components used in clotting and organ dysfunction impairs their production. Uremia (kidney dysfunction) impairs platelet function and number. Dysfunctional systemic activation of the coagulation pathway can lead to fibrin clots, microvascular thrombosis and subsequent depletion of coagulation factors and platelets. <ref type="bibr">[29]</ref> 32</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Vascular dysfunction</head><p>Refers to the ability of the vascular system to ensure sufficient end-organ perfusion.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Coagulopathy, Electrolytes and metabolites imbalance, Acidosis</head><p>This is a concept node that summarizes all possible causes of impaired vascular function (all vascular related nodes).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>33</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ischemic cardiac injury</head><p>Myocardial cell death due to insufficient oxygen to meet metabolic requirements.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hyperdynamic circulation, Hypercoagulable state, Hypoxemia</head><p>The increased cardiac output observed in hyperdynamic circulation increases the metabolic requirements of myocardial cells.</p><p>Thrombosis prevents blood from reaching the myocardial cells. Hypoxemia reduces the available oxygen in blood to meet metabolic requirements. <ref type="bibr">[11]</ref>, <ref type="bibr">[30]</ref> 34</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acute cardiac inflammation</head><p>Altered status of myocardial cells stimulated by chemical factors released by injured cells or immunological activities.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Systemic immune/inflam. response, Direct viral injury</head><p>Direct viral injury damages myocardial cells. Cell damage and death and systemic immune response stimulate local inflammation <ref type="bibr">[31]</ref>, <ref type="bibr">[32]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>35</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abnormal contractility</head><p>In this model, refers to abnormal cardiac electrophysiology, resulting in an alteration in the rate and/or coordination of contractility.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ischemic cardiac injury, Acute cardiac inflammation</head><p>Inflammation and ischemia damage and kill cells impeding the flow of electrical signaling and the coordination of contractility <ref type="bibr">[32]</ref>.</p><p>5/8 </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>37</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reduced cardiac output</head><p>A reduction in the amount of blood the heart pumps per unit time.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abnormal contractility, Reduced stroke volume</head><p>Cardiac output is a function of heart rate and stroke volume.</p><p>Reducing stroke volume decreases output. Abnormal contractility alters the heart rate <ref type="bibr">[11]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="38">Cardiac failure</head><p>Inability to adjust cardiac output to meet body's requirements.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reduced cardiac output, Electrolytes and metabolites imbalance, Acidosis</head><p>Electrolytes and metabolites imbalance and acidosis impair the heart muscles contractility, reducing cardiac output. <ref type="bibr">[33]</ref> 39 Heart stops Cessation of cardiac contractility.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Respiration stops</head><p>Hypoxemia and poor perfusion cause cellular dysfunction. In the heart this leads to failure of electrical signaling and contractility.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>40</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Liver dysfunction</head><p>The impaired ability of liver to perform multiple functional activities such as protein synthesis, metabolism of substrates, including drugs, and excretion of waste products including bile.</p><p>Reduced supply of oxygen and metabolites, Systemic immune/ inflam. response, Direct viral injury Viral damage, inflammation and poor nutrient supply damage and impair cellular function in the liver <ref type="bibr">[34]</ref>, <ref type="bibr">[35]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="41">Liver failure</head><p>The inability of the liver to perform its normal synthetic and metabolic functions, such as protein synthesis, metabolism of substrates including drugs and bile excretion.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Liver dysfunction, Acidosis</head><p>Progression of liver dysfunction, which may both result from and contributed to acidosis, may lead to synthetic and metabolic function failure <ref type="bibr">[36]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>42</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Kidney dysfunction</head><p>The impaired ability of kidney to control the body's fluid balance, maintain appropriate electrolyte concentration and eliminate substrates.</p><p>Reduced supply of oxygen and metabolites, Systemic immune/ inflam. response, Direct viral injury Direct damage, inflammation and lack of nutrients impair cellular function in the kidney, altering water and electrolyte balance capacity <ref type="bibr">[37]</ref>, <ref type="bibr">[38]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="43">Kidney failure</head><p>Kidney fails to participate in multiple functional activities such as to control the body's fluid balance, maintain appropriate electrolyte concentration and eliminate substrates.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Kidney dysfunction, Electrolytes and metabolites imbalance, Acidosis</head><p>Significant and widespread damage to the cells in the kidney resulting in loss of function. Acid-base, electrolytes and metabolites imbalance place competing strains on limited homeostasis capacity. <ref type="bibr">[18]</ref> 44</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hematologic dysfunction</head><p>The ability of bone marrow to produce blood cells.</p><p>Reduced supply of oxygen and metabolites, Systemic immune/ inflam. response, Direct viral injury Viral damage, inflammation and poor nutrient supply damage and impair cellular function in the bone marrow <ref type="bibr">[39]</ref>.</p><p>6/8 Bone marrow fails to produce blood cells.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Marrow dysfunction, Electrolytes and metabolites imbalance, Acidosis</head><p>Significant and widespread damage to the cells in the bone marrow through lack of nutrients and direct damage <ref type="bibr">[39]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="46">Gut dysfunction</head><p>The impaired ability of gut to participate in its usual functional activities such as the digestion, absorption of nutrients and the excretion of waste.</p><p>Reduced supply of oxygen and metabolites, Systemic immune response, Direct viral injury Direct viral injury of enterocytes, systemic inflammation and hypoperfusion may impair gastrointestinal tract function <ref type="bibr">[40]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="47">Gut failure</head><p>Gut fails to participate in its usual functional activities such as the digestion, absorption of nutrients and the excretion of waste.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Gut dysfunction, Electrolytes and metabolites imbalance, Acidosis</head><p>Severe gastrointestinal dysfunction may result in gut failure with reduction of gut function below the minimum necessary for absorption of macronutrients, water and electrolytes. The metabolic and electrolyte disturbances associated with systemic sepsis and inflammation may contribute to gut failure <ref type="bibr">[41]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>48</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Brainstem dysfunction</head><p>The impaired ability of the brainstem to perform baseline function including mediating sensory and motor pathways between the spinal cord and the brain, controlling brainstem reflexes, the sleepwake cycle and autonomic control of the cardiocirculatory, respiratory, digestive and immune systems.</p><p>Systemic immune/inflam. response, Reduced supply of oxygen and metabolites</p><p>The brainstem is prone to vascular and inflammatory insults including compromised brainstem perfusion from impaired autoregulation of cerebral blood flow from sepsis; neuroinflammatory processes from excessive systemic inflammatory response; and metabolic disturbance including electrolyte disturbance and renal or liver failure <ref type="bibr">[42]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>49</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Brainstem failure</head><p>The complete loss of brainstem function.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Electrolytes and metabolites imbalance, Acidosis, Brainstem dysfunction</head><p>Complete cessation of brainstem reflexes and functions with irreversible loss of consciousness and the capacity to breath, leading to cardiocirculatory and respiratory failure and death <ref type="bibr">[42]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>50</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cortical brain dysfunction</head><p>The impaired ability of the central nervous system to perform baseline function including normal level of consciousness and cognitive processes.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Systemic immune response, Reduced supply of oxygen and metabolites</head><p>Diffuse cerebral dysfunction due to the systemic inflammatory response to infection without direct central nervous system infection, mediated via excessive microglial activation, impaired cerebral perfusion, blood-brain-barrier dysfunction and altered neurotransmission. Severe hypoxemia and glucose dysregulation can potentiate dysfunction. <ref type="bibr">[43]</ref> 51 Coma   A state of prolonged unresponsiveness with inability to respond appropriately to stimuli.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Liver dysfunction, Electrolytes and metabolites imbalance, Acidosis, Cortical brain dysfunction</head><p>Significant cortical brain dysfunction from sepsis, metabolic and electrolyte disturbance may result in coma <ref type="bibr">[43]</ref>. Severe liver dysfunction may result in hyperammonemia with neuronal dysfunction and cerebral edema, with progression to coma <ref type="bibr">[44]</ref>.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig 1 .</head><label>1</label><figDesc>Fig 1. Causal DAG excerpt. These are the initial nodes of the Respiratory causal DAG provided in S1 Fig. The node Pulmonary capillary leakage, for example, has three 'parents' that jointly influence it, and two 'children' it influences.In the BN, provided in S1 Model, the variable it represents has states and a CPT that are not shown in the DAG. All the nodes are named, numbered, and color coded for ease of reference, and corresponding definitions for variables and arcs are given in the associated Dictionary, S1 Table, an excerpt from which is provided in Fig.2.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig 2 .</head><label>2</label><figDesc>Fig 2. BN Dictionary excerpt: In the Dictionaries, descriptions of the variables and arcs are provided, with selected supporting references. The variables are numbered, named and color coded as in the causal DAGs and BN files. The full Dictionaries are provided as S1Table and S2 Table.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 4</head><label>4</label><figDesc>Fig.4illustrates the same sequence of elicitation session types (left column), and how they relate to two more detailed elicitation procedures. To maximize the value of each session, a sequence of associated tasks was performed before and after the session itself (middle column). This work was most extensive for the group elicitation session, and is detailed below, but the work was repeated to a lesser extent for each of the one-on-one sessions.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Februaryโข</head><label></label><figDesc>: TS leveraged existing clinical and research networks to enlist contributions from domain experts. We directly emailed individuals as well as a national infectious diseases clinical mailing list, inviting them to complete a web-based survey (via the Survey Monkey tool). This served multiple purposes. First, it elicited initial information on the potential causal model. Since we expected many people would not fully complete the survey, we shuffled blocks of questions randomly so that participants and session format โข context for this workshop โข model starting template โข discussion to clarify the modeling goal Facilitator asks iteratively: 1. What new variables are relevant? 2. (if clarifying:) What are their possible states? 3. For each new variable: a. Which others are direct causes? b. Which others are direct effects? c. (if applicable:) Does this new mediator supersede the old direct connection?</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>(</head><label></label><figDesc>100 questions over 5 pages), the amount participants managed to complete was taken to be an implicit measure of their engagement. We then used other techniques to increase engagement before the workshop, such as distributing recent model diagrams and descriptions (or important excerpts), and asking a few more open-ended questions.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>6 .</head><label>6</label><figDesc>cluded "housekeeping" such as introductions and the format of the session, a summary of the problem space and the goals of the workshop, the starting template for the model, and any other supporting materials. We raised the general issue of what question the model is trying to answer, and tried to achieve an expert consensus on this. We then proceeded to a standard set of questions for eliciting causal structure, applied in an adaptive and iterative fashion. We asked about which factors (variables) are relevant, and only asked about their possible states if it was important to help define them. Experts frequently suggested clarification of the concepts intended to be captured by existing variables or modification of their names as elicitation progressed, and sometimes suggested merging and separating variables. We asked about the causal relationships between them, usually focusing on one variable at a time and asking which other variables are direct causes and which are direct effects (a localized version of the "bow tie" method used for risk analysis<ref type="bibr" target="#b57">[49]</ref>). When new variables were added and connected, we February 14, 2022 13/32 Modeling COVID-19 disease processes by eliciting causal BNs Mascaro et al. also asked if this superseded any prior direct connection between a parent and a child of the new variable. Experts sometimes pointed out that a relationship could be bidirectional, which we noted, but in this initial non-dynamic graph we displayed only one direction. We chose a direction that created no cycle, and was either the initial influence, or the more immediate (i.e., with less time delay), or the strongest, as deemed most informative for disease progression or most pertinent to a submodel's goal. We also noted any other comments, such as which connections were more important, unusual, or controversial. Experts sometimes clarified thebasis for their suggestions by referring to the literature or their own opinion. The primary outcome of the workshop was a causal DAG (in the GeNIe BN software) that a high proportion of experts agreed captured the most important underlying pathophysiological processes. Post-workshop review: After the workshop, our team had a debrief discussion (30-60 min), for feedback on their own performance and to consolidate their understanding. Subsequently, the modelers cleaned up any loose ends in the model or documentation, making sure all the knowledge elicited was understood and documented correctly, and simultaneously looking for gaps that would need further clarification. This included indicative parameters and typical scenarios, as described above. The whole workshop, conducted remotely by web-based videoconference (Zoom), was recorded as video, and the audio later transcribed into text. This allowed us to review any part of the elicitation as required. Our transcripts and video recordings,</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>1 .</head><label>1</label><figDesc>Causal DAGs and BNs, in which we specify the causal structures in supplementary static graph diagrams (S1 Fig., S2 Fig.) and in supplementary GeNIe BN files (S1 Model, S2 Model). GeNIe can present the structures simply as causal DAGs, or more dynamically: variables can be displayed with their states and indicative probabilities, and the states of variables can be specified to explore how this changes the probability distributions over other variables' states.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head></head><label></label><figDesc>not profound enough to require presentation as competing DAGs; our list of issues is sufficient to indicate which structural components would differ. Some disagreements only concern the degree of impact of alternative pathways, which corresponds to differing numerical parameterizations of the BNs, and no parameterizations are included here. Both our BNs do not include important background factors such as age, comorbidities and vaccination status, that strongly influence the probability of more serious COVID-19 outcomes (and each other). Knowledge about their role in the COVID-19 process was too limited: although they are known to directly influence some of our variables (e.g., vaccination reduces the chance of initial infection), not all of their direct influences are clear (e.g., vaccination also decreases the chance of infection developing into severe COVID-19, probably by influencing multiple variables along these pathways</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_8"><head></head><label></label><figDesc>Respiratory causal DAG (S1 Fig.) models the physiological process underlying COVID-19 in the respiratory system, outlining multiple and often concurrent pathways from the initial replication of the virus to key downstream complications such as multi-organ failure.We color-coded the nodes: pink for the Infection process, yellow for more detailed mechanisms relevant to the Pulmonary system, orange for those Complications that mainly arise directly from the respiratory system, and cyan for a selection of Signs and Symptoms included only for illustrative purposes. "Virus" refers to SARS-CoV-2.References have been omitted from the following description, but can be found in the associated variable entries in the BN dictionary.Infection processAfteran exposure event, the virus can enter the upper respiratory tract via the nasopharynx (Virus enters upper respiratory tract) and may replicate locally and cause inflammation at various locations in the respiratory system, including the epithelial cells of the upper respiratory tract (Upper respiratory tract epithelial infection) and the lower respiratory tract (Alveolar epithelial infection). Direct infection involving the alveoli without preceding or simultaneous infection involving the upper respiratory tract is possible, although it may be less likely. The virus can first become established at one site then spread to or re-establish in another. For example, Infection of olfactory epithelium following epithelial infection in the upper respiratory tract has manifested as Ageusia and/or anosmia in some patients. The virus may spread from epithelial to endothelial cells in alveoli, causing February 14, 2022 18/32 Modeling COVID-19 disease processes by eliciting causal BNs Mascaro et al. Alveolar endothelial infection. During all infection processes, the virus may enter the bloodstream (Viremia) and potentially spread to other parts of the body (not included here).Viral replication at any site may activate Systemic immune and inflammatory response, which often results in the release of pro-and/or anti-inflammatory blood markers from immunerelated cells.Pulmonary systemThe primary function of the respiratory system is to support the metabolic processes of the body by taking in oxygen and removing carbon dioxide; this occurs through gas exchange between air and blood at the delicate membranes of the lung alveoli. Our Respiratory causal DAG (S1 Fig.) models the initial pathophysiological process which is initiated by SARS-CoV-2 infection in this system. The most notable large-scale feature is the three distinct pathways from the initial infection to involvement of the respiratory system and then complications, although these pathways have interconnections and often contribute concurrently. Mechanical pathway: Alveolar and systemic inflammation can damage pulmonary capillaries causing the leakage of plasma (Pulmonary capillary leakage), leading to filling of the alveoli with exudate (Alveolar consolidation) that causes stiffening and reduced mechanical lung function (Reduced lung compliance), and results in Ventilatory insufficiency. Alveolar epithelial infection (and inflammation) can also directly reduce compliance, but to a lesser extent. Another possible cause of ventilatory insufficiency is a loss of muscle mass (Muscle wasting) which can be directly caused by catabolism as a result of the systemic immune response and may be affected by a range of background factors, such as nutritional status and immobility, not shown in this model. Gas exchange pathway: Pulmonary capillary leakage and alveolar consolidation blocks the passage of air and reduces the alveolar surface area available for gas exchange, and this mismatch between ventilation and blood perfusion reduces gas exchange in the affected parts of the lungs (V/Q mismatch). At an extreme, local perfusion may occur in the absence of ventilation with oxygenated air (Shunt). Alveolar infection causes local Hypoxia which can trigger counteracting Pulmonary vasoconstriction, an adaptive physiological response which helps to match regional perfusion to ventilation in the lungs and thus reduces the extent of V/Q mismatch. Coagulation pathway: Endothelial infection/ inflammation and possibly the presence of virus in the blood (viremia) may trigger a systemic immune and inflammatory response, and this may result in an abnormally high propensity to coagulation (Hypercoagulable state). This may begin locally in the small vessels of the lower airways (Pulmonary microthromboses), but can later manifest as macroscopic thromboses in larger vessels (Other thromboses). Both types of thrombosis can block vessels in the lungs (Pulmonary circulatory blockage) and lead to V/Q mismatch, to which alveolar endothelial infection/inflammation can also directly contribute. The direct consequences of impaired lung function, due to any of these pathways, include insufficient blood oxygenation (Hypoxemia) and excessive blood carbon dioxide (Hypercapnia), which can be measured using blood gas assays or by pulse oximetry for oxygen. Furthermore, February 14, 2022 19/32 Modeling COVID-19 disease processes by eliciting causal BNs Mascaro et al. pulmonary vasoconstriction caused by hypoxia and pulmonary circulatory obstruction caused by thrombosis can produce raised blood pressure in the pulmonary arteries (Pulmonary hypertension),</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_9"><head></head><label></label><figDesc>Respiratory model includes and summarizes some key complications. The lungs interact most closely with the heart; so in addition to pulmonary hypertension, pulmonary thrombosis can directly cause impaired cardiac output. Systemic immune response and insufficient oxygen in the blood (i.e., hypoxemia) can also lead to impaired cardiac output via Diminished myocardial contractility. Maintaining end organ tissue oxygenation relies on sufficient oxygen transport via the blood, so Hypoxia occurs where there is hypoxemia or insufficient blood perfusion due to impaired cardiac output. Hypoxia can directly cause organ failure, or Multi-organ failure if more than one is affected (which is often the case). Other pathways that can eventually lead to multi-organ failure include virus in the bloodstream causing direct viral injury to organs, and an extreme systemic immune response (i.e., cytokine storm). Several mechanisms can trigger the body's sensor for insufficient oxygen, including reduced compliance (i.e., a mechanical failure of the lungs), hypoxemia, hypercapnia, and acidosis (both respiratory and metabolic). If the body senses there is insufficient oxygen supply (Perceived need for air), it demands more oxygen intake, which manifests as Dyspnea, one of the most important symptoms for COVID-19.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_10"><head></head><label></label><figDesc>model that seem noteworthy, either in themselves or as illustrative examples. Some issues involve modeling choices: even where the process being represented is entirely agreed upon, modeling sometimes involves choices about how to represent it, and some of the options we chose here may need clarification or appear controversial. Some issues involve domain knowledge: there are some aspects of COVID-19 that are still not fully understood, about which there may be competing hypotheses. So, some of the options we chose here may need revision in future as further research resolves these controversies. Upper respiratory tract mediation: One theoretical controversy, related to the diagnostic value of a dry cough, concerns three possible respiratory pathways by which the virus enters the body. Respiratory viruses are thought to typically infect the upper respiratory tract first (abbreviated as URT in the BN), then descend by contiguous spread to the alveoli and (rarely) via the bloodstream. COVID-19 may take this normal path, or may bypass the upper respiratory tract or the larger airways to infect the endothelium of the lower airways more directly via the ACE2 receptor, or less directly from the upper respiratory tract via the bloodstream. The data on this issue is currently limited so we have included all three pathways in the model, but our experts thought the typical path for respiratory viruses was less likely than the other two. Future findings may support this opinion and clarify their relative importance. February 14, 2022 20/32 Modeling COVID-19 disease processes by eliciting causal BNs Mascaro et al. Vascular lung damage feedback loops: A high degree of vascular lung damage, caused by microthromboses in lung capillaries, appears to be a unique feature of COVID-19. Our Respiratory BN includes vascular involvement (in the Coagulation pathway) primarily as a mediator for the initial phase of infection in the lung, whereas our Complications BN places more emphasis on subsequent feedback loops. Since vascular involvement is complicated, we explored it by eliciting a separate vascular model from two of our experts, which is not presented here. We were satisfied that the vascular elements included in our Respiratory and Complications models were sufficient for our purposes. V/Q mismatch and Shunt seem logically related: It is good practice to avoid including logically related terms in a causal model, i.e., where their semantics results in a logical dependence. Such a connection results in probabilistic dependence and an arc in the model, but it may behave differently to a causal connection under intervention, which can make it difficult to adapt the model for decision support. Here we included both Shunt and V/Q mismatch, even though shunt is (by definition) a type of V/Q mismatch, so the former logically entails the latter. This accurately represents the statements elicited: our experts consistently used both these terms and distinguished between them. They had good reason: different interventions (such as positive airway pressure for shunt and supplementary oxygen for V/Q mismatch) are considered appropriate in each case. So, mirroring their terminology faithfully captures expert knowledge in a way they can agree is accurate, which in this case includes the relevant causal connections to interventions or tests.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_11"><head></head><label></label><figDesc>) models the main physiological processes underlying the progression of COVID-19 from the initial infection in the respiratory system to complications in other organs. As before, the BN dictionary notes some key feedback loops and provides references for the mechanisms associated with each variable mentioned below.OverviewThe model explicitly describes the status (dysfunction) of nine key organ systems, namely, respiratory, vascular, cardiac, liver, kidney, hematologic, gastrointestinal, cortical and brainstem dysfunctions. Among these, we choose to paint a more fine-grained picture of the Vascular (nodes in blue) and Cardiac (nodes in green) systems due to their potential earlier involvement, as well as more significant System-wide impact (nodes in off-white) on Other organs (nodes in orange). The full picture of the pulmonary system is shown in the Respiratory model; here we retained a few key Pulmonary variables (nodes in yellow) and two major consequences of pulmonary dysfunction due to their system-wide February 14, 2022 21/32 Modeling COVID-19 disease processes by eliciting causal BNs Mascaro et al. impact: Hypoxemia and Hypercapnia. Two Background factors (nodes in purple) are added only for illustrative purposes. Pulmonary system and direct viral impact Despite its initial establishment in the pulmonary system, infection with SARS-CoV-2 can potentially drive the dysfunction of all listed organ systems directly via two main mechanisms, Direct viral injury and the Systemic immune/inflammatory response, throughout the entire process of the disease. In particular, they both can affect the vascular system by reducing Vascular integrity and Vascular tone. Vascular integrity refers to the status of endothelial structure compromising permeability, and the vascular tone refers to the degree of constriction of a blood vessel. The systemic inflammatory response can additionally increase the probability of Hypercoagulable state (as also depicted in the Respiratory model) and Dehydration. For the cardiac system, direct viral injury and the systemic inflammatory response might both result in Acute cardiac inflammation. Vascular system The vascular function (in this model) represents the ability of blood vessels to ensure sufficient blood circulation to meet the metabolic needs and energy requirements of the organs. Reduced vascular tone, Reduced vascular integrity and Hypercoagulable state are three major mechanisms that contribute to vascular dysfunction. The first two mechanisms can both lead to Reduced functional intravascular volume, i.e., less blood is available to supply the organs because of the loss of vascular tone or the shift of intravascular fluid to the interstitium (Fluid shift to interstitium) due to altered permeability (vascular integrity).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_12"><head>February</head><label></label><figDesc>19 disease processes by eliciting causal BNs Mascaro et al.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_13"><head>Representing current and future under-standing</head><label></label><figDesc>The two fully documented models presented here are the first published causal DAGs of COVID-19 pathophysiology. Confidence in their quality is underwritten by the rigorous process used to create them. They can be used as a visual aid to understanding and explaining the internal causal processes and remaining controversies of COVID-19, and are accessible to audiences without specialist medical expertise.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_14"><head></head><label></label><figDesc>DAGs help researchers identify relevant factors, and more specifically, factors that are potential mediators, confounders, and sources of selection bias or measurement error. So, we anticipate that our models will serve as a guide to the design of cohort and case-control studies of the effects of various demographic and clinical risk factors, or of the effects of various interventions, on one of several clinical outcomes of interest for SARS-CoV-2 infection.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_15"><head></head><label></label><figDesc>Decision and utility nodes may be added to the theoretical or application models, to allow causal BNs to formally model and predict the consequences of therapeutic interventions, which is essential for clinical reasoning and decision making. As new data accrues on the impacts of such interventions, the application models can be re-parameterized to remain accurate.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_16"><head></head><label></label><figDesc>nosis and management of COVID-19 patients and another to support resource management and monitoring for confirmed cases. For the in-hospital prognosis tool, available information about the patient can be entered into the tool by a clinician directly, or retrieved automatically from a patient's record. The clinician will then receive information not just on the patient's overall prognosis, but also on risks around organs, body functions and treatment requirements over the next 24 hours and the next 5 days. For resource management, the same application model can be used, but integrated into existing, centralized, government monitoring systems. The model would be used for confirmed cases being monitored at home or in non-medical facilities to quickly flag those at risk, allowing ministry staff to make better informed and more finegrained decisions around utilization of hospital and medical resources.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_17"><head>Fig. Respiratory causal DAG v3. 8 . 8 .</head><label>88</label><figDesc>This depicts the initial pathophysiological process of SARS-CoV-2 in the respiratory system, outlining multiple and often concurrent pathways from viral infection to key downstream complications such as multi-organ failure. Some variables are latent (i.e., not directly observable) but their probability distributions can be inferred from observable evidence such as clinical signs, symptoms and laboratory measurements, not all of which are shown in the diagram. Many mechanisms described in the BN can be influenced by background factors such as age, sex, and comorbidities, which are also not shown. BNs are acyclic, so feedback loops that may occur as the disease progresses are not included in the diagram. We divide the nodes into four color-coded categories: Infection process (pink), February 14, 2022 28/32 Modeling COVID-19 disease processes by eliciting causal BNs Mascaro et al. Pulmonary details (yellow), resulting Complications (orange), and a few illustrative examples of Signs and symptoms (cyan). Within the pulmonary system, we distinguish (using background boxes) three pathways from Infection to possible Complications: involving problems with Mechanical operation of the lungs, Gas exchange, and Coagulation. S2 Fig. Complications causal DAG v3.This depicts the main physiological processes underlying the progression of COVID-19 from the initial infection in the Pulmonary system (nodes in yellow) to complications in other organs. Vascular (nodes in blue) and Cardiac (nodes in green) systems are modeled in more detail due to their likely earlier involvement and greater system-wide impact on Other Organs (nodes in orange), i.e., liver, kidney, hematologic, gastrointestinal, cortical and brainstem dysfunction. Mechanisms that have a systemwide impact are colored in off-white, and we include two illustrative examples of background factors (nodes in purple). S1 Model. Respiratory BN v3.8 (indicative parameters only). This BN file for the Respiratory model may be viewed, manipulated and edited in the GeNIe application (https: //www.bayesfusion.com/genie/), which is free for academic use, or reformatted for other BN software. The network structure is depicted in S1 Fig., and in addition the BN includes states for each variable and parameters specifying their influence (which are only rough indications based on our elicitation sessions and literature reviews). S2 Model. Complications BN v3.8 (indicative parameters only). This BN file for the Complications model may be viewed, manipu-lated and edited in the GeNIe application (https: //www.bayesfusion.com/genie/), which is free for academic use, or reformatted for other BN software. The network structure is depicted in S2 Fig., and in addition the BN includes states for each variable and parameters specifying their influence (which are only rough indications based on our elicitation sessions and literature reviews).S1</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_18"><head>Table .</head><label>.</label><figDesc>Respiratory BN dictionary v3.8.</figDesc><table><row><cell>This table for the Respiratory BN specifies, for</cell></row><row><cell>each variable, a description of the variable and</cell></row><row><cell>its relationships to its parent nodes, supported</cell></row><row><cell>by references to academic literature listed in a</cell></row><row><cell>bibliography. Relevant evidence, background</cell></row><row><cell>factors, and some feedback loops are noted even</cell></row><row><cell>if not included in the BN diagram.</cell></row></table><note><p><p>S2</p>Table. Complications BN dictionary v3.8. This table for the Complications BN specifies, for each variable, a description of the variable and its relationships to its parent nodes, supported by references to academic literature listed in a bibliography. Relevant evidence, background factors, and some feedback loops are noted even if not included in the BN diagram.</p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_19"><head>S3 Table. Members of COVID BN Ad-</head><label></label><figDesc></figDesc><table><row><cell>S1</cell></row><row><cell>visory Group v1.2. This table lists all the</cell></row><row><cell>members of our COVID BN Advisory Group</cell></row><row><cell>who opted to be individually acknowledged, with</cell></row><row><cell>their institutions and relevant qualifications. 1/5</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_20"><head>Table. Respiratory BN dictionary v3.8</head><label></label><figDesc>Supplement prepared for Mascaro et al (2021); reuse freely with acknowledgement.</figDesc><table><row><cell cols="2">ID Variable name</cell><cell>Description</cell><cell>Parent nodes</cell><cell>Relationships with parent nodes</cell></row><row><cell></cell><cell></cell><cell>Air filtration is an important component</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>of nasopharyngeal function. SARS-CoV-</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Virus enters</cell><cell>2 viral particles enter the upper</cell><cell></cell><cell></cell></row><row><cell>1</cell><cell>upper respiratory</cell><cell>respiratory tract and become trapped on</cell><cell>None</cell><cell>NA</cell></row><row><cell></cell><cell>tract (URT)</cell><cell>mucosal surfaces. The amount of virus is</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>dependent on exposure related factors,</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>not included in the current model.</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Upper respiratory</cell><cell>Viral tropism of upper respiratory tract</cell><cell></cell><cell></cell></row><row><cell>2</cell><cell>tract (URT) epithelial</cell><cell>epithelial cells, signaling an immune response and leading to an altered state</cell><cell>Virus enters upper respiratory tract</cell><cell>SARS-CoV-2 infection begins in the upper respiratory tract [1] causing infection of the epithelial cells in the upper respiratory tract.</cell></row><row><cell></cell><cell>infection</cell><cell>of cells (local inflammation)</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_25"><head>ID Variable name Description Parent nodes Relationships with parent nodes 28 Hypercoagulable state</head><label></label><figDesc></figDesc><table><row><cell>Increased propensity to coagulate due to a</cell><cell>Systemic immune/inflam.</cell></row><row><cell>high level of clotting factors and</cell><cell>response, Reduced vascular</cell></row><row><cell>molecules.</cell><cell>integrity, Alveolar inflammation</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_26"><head>ID Variable name Description Parent nodes Relationships with parent nodes 36 Reduced stroke volume</head><label></label><figDesc>The volume of blood ejected from the heart with each left ventricular cardiac muscle contraction event or heart beat is reduced.The stroke volume is dependent on the volume of blood filling the left ventricle before contracting. Reduced functional intravascular volume and pulmonary hypertension lower this volume of blood. Hyperdynamic circulation reduces time for filling to occur. Ischemic cardiac injury, acute cardiac inflammation and abnormal contractility impair weaken and disrupt myocardial ability to eject from the left ventricle. Increased vascular resistance leads to reduced stroke volume via diminished ventricular compliance.[32]    </figDesc><table><row><cell>Reduced functional intravascular</cell></row><row><cell>volume, Ischemic cardiac injury,</cell></row><row><cell>Acute cardiac inflammation,</cell></row><row><cell>Pulmonary hypertension,</cell></row><row><cell>Hyperdynamic circulation,</cell></row><row><cell>Abnormal contractility, Vascular</cell></row><row><cell>resistance</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_27"><head>ID Variable name Description Parent nodes Relationships with parent nodes 45 Hematologic failure</head><label></label><figDesc></figDesc><table /></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div><head>Acknowledgments</head><p>This publication is supported by <rs type="funder">Digital Health CRC</rs> Limited funded under the <rs type="funder">Australian Commonwealth Government's Cooperative Research Centres Programme</rs> and The <rs type="funder">Snow Medical Research Foundation</rs>. We thank all experts and our February <rs type="grantNumber">14</rs>, <rs type="grantNumber">2022 29/32 5/5 Selected References 7/8</rs></p><p>Selected References</p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_9Pbrayv">
					<idno type="grant-number">14</idno>
				</org>
				<org type="funding" xml:id="_YBZ4uFw">
					<idno type="grant-number">2022 29/32 5/5 Selected References 7/8</idno>
				</org>
			</listOrg>

			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>AgenaRisk (<ref type="url" target="https://www.agenarisk.com/">https://www.agenarisk. com/</ref>), and BayesiaLab (<ref type="url" target="http://www.bayesia.com/">http://www.bayesia.com/</ref>). In addition, research software and tools include Elvira (<ref type="url" target="http://leo.ugr.es/elvira/">http://leo.ugr.es/elvira/</ref>), R BN libraries (http:// www.bnlearn.com/), BNT (<ref type="url" target="https://github.com/bayesnet/bnt/">https://github.com/bayesnet/ bnt/</ref>), SamIam (<ref type="url" target="http://reasoning.cs.ucla.edu/samiam/">http://reasoning.cs.ucla.edu/samiam/</ref>), and BayesPy (<ref type="url" target="https://pypi.org/project/bayespy/">https://pypi.org/project/bayespy/</ref>).</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>We also thank Dr Sally Shrapnel for helpful feedback on the draft of this article. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>S2</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>4</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Respiratory infection</head><p>Viral replication occurring at one or more sites of the body, primarily initiating in the nasopharynx.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Virus enters upper respiratory tract, Upregulation of ACE2 receptors</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>SARS-CoV-2 enters human cells by binding with Angiotensin</head><p>Converting Enzyme-2 (ACE-2), which is highly expressed in nasal epithelial cells <ref type="bibr">[1]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>5</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Alveolar inflammation</head><p>Viral tropism of the cells of the alveoli, inducing an immune response which causes to an altered cellular state (local inflammation).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Respiratory infection, Systemic immune/ inflam. response</head><p>The upper airways act as portals for SARS-CoV-2 entry and infection of the alveolar epithelium and endothelium <ref type="bibr">[2]</ref>, <ref type="bibr">[3]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>6</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pulmonary dysfunction</head><p>Impairment of the pulmonary system capacity to oxygenate blood and removing carbon dioxide (gas exchange).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Direct viral injury, Systemic immune/ inflam. response, Alveolar inflammation, Hypercoagulable state</head><p>Gas exchange can be impaired due to injury of alveolar cells, pulmonary capillary leakage (caused by both the virus and immune activities), pulmonary circulatory blockage (due to microthromboses), and ventilatory insufficiency (due to reduced compliance and effort). (See details in the respiratory model)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>7</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pulmonary hypertension</head><p>High blood pressure in vascular tree of the lung.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hypercoagulable state, Hypoxemia</head><p>Elevated blood pressure in the lungs can be due to blood clots (microthromboses and pulmonary emboli), and vasoconstriction (triggered by hypoxemia) <ref type="bibr">[4]</ref>- <ref type="bibr">[6]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>8</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Respiratory failure</head><p>Inability of the lungs to perform gasexchange to oxygenate the blood and remove carbon dioxide.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pulmonary dysfunction, Pulmonary hypertension, brainstem dysfunction, Acidosis, Coma</head><p>Hypoventilation (brain and coma) reduces amount of new air entering the lungs for gas exchange. Pulmonary dysfunction and hypertension diminish the blood flow through the lungs. Acidosis increases the amount of carbon dioxide that needs to be exchanged. <ref type="bibr">[7]</ref> S3 Table . Members of COVID BN Advisory Group v1.2</p><p>The following members agreed to be acknowledged individually; others preferred to remain anonymous. We thank all members for participating in the elicitation sessions, including group workshops, one-on-one meetings, and surveys. This supplement was prepared for Mascaro et al (2021); reuse freely with acknowledgement.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients</title>
		<author>
			<persName><forename type="first">L</forename><surname>Zou</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMc2001737</idno>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<date type="published" when="2020-02">Feb. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19</title>
		<author>
			<persName><forename type="first">J</forename><surname>Meinhardt</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41593-020-00758-5</idno>
	</analytic>
	<monogr>
		<title level="j">Nat. Neurosci</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">2</biblScope>
			<date type="published" when="2021-02">Feb. 2021</date>
			<pubPlace>Art</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Brann</surname></persName>
		</author>
		<idno type="DOI">10.1126/sciadv.abc5801</idno>
	</analytic>
	<monogr>
		<title level="j">Sci. Adv</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">31</biblScope>
			<date type="published" when="2020-07">Jul. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P Y</forename><surname>Hui</surname></persName>
		</author>
		<idno type="DOI">10.1016/S2213-2600(20)30193-4</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet Respir. Med</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="687" to="695" />
			<date type="published" when="2020-07">Jul. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Silent&apos; Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Bickler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Feiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Lipnick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Mckleroy</surname></persName>
		</author>
		<idno type="DOI">10.1097/ALN.0000000000003578</idno>
	</analytic>
	<monogr>
		<title level="j">Anesthesiology</title>
		<imprint>
			<date type="published" when="2020-09">Sep. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">The pathophysiology of &apos;happy&apos; hypoxemia in COVID-19</title>
		<author>
			<persName><forename type="first">S</forename><surname>Dhont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Derom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Van Braeckel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Depuydt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">N</forename><surname>Lambrecht</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12931-020-01462-5</idno>
	</analytic>
	<monogr>
		<title level="j">Respir. Res</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">1</biblScope>
			<date type="published" when="2020-07">Jul. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Physiologic Improvement in Respiratory Acidosis Using Extracorporeal Co2 Removal with Hemolung Respiratory Assist System in the Management of Severe Respiratory Failure from Coronavirus Disease 2019</title>
		<author>
			<persName><forename type="first">B</forename><surname>Akkanti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit. Care Explor</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">3</biblScope>
			<date type="published" when="2021-03">Mar. 2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">The carnage of substandard research during the COVID-19 pandemic: a call for quality</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Bramstedt</surname></persName>
		</author>
		<idno type="DOI">10.1136/medethics-2020-106494</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Medical Ethics</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="803" to="807" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title level="m" type="main">Bayesian Artificial Intelligence. 2nd ed</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Korb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Nicholson</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2011">2011</date>
			<publisher>Chapman &amp; Hall / CRC Press</publisher>
			<pubPlace>Boca Raton</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Dynamic models for Coronavirus Disease 2019 and data analysis</title>
		<author>
			<persName><forename type="first">N</forename><surname>Shao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chen</forename><forename type="middle">W</forename></persName>
		</author>
		<idno type="DOI">10.1002/mma.6345</idno>
	</analytic>
	<monogr>
		<title level="j">Mathematical Methods in the Applied Sciences</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="4943" to="4949" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Novel Coronavirus 2019 (Covid-19) epidemic scale estimation: topological network-based infection dynamics model</title>
		<author>
			<persName><forename type="first">K</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1101/2020.02.20.20023572</idno>
	</analytic>
	<monogr>
		<title level="j">medRxiv</title>
		<imprint>
			<date type="published" when="2020-03-03">2020. Mar 3</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pandey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Bai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fitzpatrick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chinazzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Piontti</surname></persName>
		</author>
		<idno type="DOI">10.1016/S2468-2667(21)00002-5</idno>
	</analytic>
	<monogr>
		<title level="j">The Lancet Public Health</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="184" to="191" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Modelling the impact of COVID-19 on intensive care services in New South Wales</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Fox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Trauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mcbryde</surname></persName>
		</author>
		<idno type="DOI">10.5694/mja2.50606</idno>
	</analytic>
	<monogr>
		<title level="j">Medical Journal of Australia</title>
		<imprint>
			<biblScope unit="volume">212</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="468" to="469" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Early dynamics of transmission and control of COVID-19: a mathematical modelling study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kucharski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Diamond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Edmunds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Funk</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1473-3099</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="30144" to="30144" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Risk estimation and prediction of the transmission of coronavirus disease-2019 (COVID-19) in the mainland of China excluding Hubei province</title>
		<author>
			<persName><forename type="first">H</forename><surname>Wan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Yang</surname></persName>
		</author>
		<idno type="DOI">10.1186/s40249-020-00683-6</idno>
	</analytic>
	<monogr>
		<title level="j">Infect Dis Poverty</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">116</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Dynamic causal modelling of COVID-19</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Friston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Parr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zeidman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Razi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Flandin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Daunizeau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">arXiv</title>
		<imprint>
			<biblScope unit="page">4463</biblScope>
			<date type="published" when="2004">2020. Apr 9. 2004</date>
		</imprint>
	</monogr>
	<note>q-bio.PE</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Estimating required &apos;lockdown&apos; cycles before immunity to SARS-CoV-2: Model-based analyses of susceptible population sizes</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Moran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Fagerholm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cullen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Daunizeau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Richardson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Williams</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">seven European countries including the UK and Ireland</title>
		<imprint>
			<date type="published" when="2004">2020. Apr 9. 2004</date>
			<biblScope unit="page">5060</biblScope>
		</imprint>
	</monogr>
	<note>S0. q-bio.PE</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">COVID-19 infection and death rates: the need to incorporate causal explanations for the data and avoid bias in testing</title>
		<author>
			<persName><forename type="first">N</forename><surname>Fenton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Neil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Osman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mclachlan</surname></persName>
		</author>
		<idno type="DOI">10.1080/13669877.2020.1756381</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Risk Research</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1" to="4" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<monogr>
		<title level="m" type="main">Probabilistic Reasoning in Intelligent Systems: Networks of Plausible Inference</title>
		<author>
			<persName><forename type="first">J</forename><surname>Pearl</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1988">1988</date>
			<publisher>Morgan Kaufmann</publisher>
			<pubPlace>San Mateo</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<monogr>
		<author>
			<persName><forename type="first">P</forename><surname>Spirtes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">N</forename><surname>Glymour</surname></persName>
		</author>
		<title level="m">Scheines R. Causation, Prediction, and Search. 2nd ed</title>
		<meeting><address><addrLine>Cambridge, MA</addrLine></address></meeting>
		<imprint>
			<publisher>MIT Press</publisher>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title level="m" type="main">The Cambridge Handbook of Artificial Intelligence</title>
		<author>
			<persName><forename type="first">N</forename><surname>Bostrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Yudkowsky</surname></persName>
		</author>
		<editor>Frankish K, Ramsey WM</editor>
		<imprint>
			<date type="published" when="2014">2014</date>
			<publisher>Cambridge University Press</publisher>
			<biblScope unit="page" from="316" to="334" />
		</imprint>
	</monogr>
	<note>The ethics of artificial intelligence</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Explaining Bayesian Networks in Natural Language: State of the Art and Challenges</title>
		<author>
			<persName><forename type="first">C</forename><surname>Hennessy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bugarรญn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Reiter</surname></persName>
		</author>
		<ptr target="https://aclanthology.org/2020.nl4xai-1.7" />
	</analytic>
	<monogr>
		<title level="m">2nd Workshop on Interactive Natural Language Technology for Explainable Artificial Intelligence</title>
		<meeting><address><addrLine>Dublin, Ireland</addrLine></address></meeting>
		<imprint>
			<publisher>Association for Computational Linguistics</publisher>
			<date type="published" when="2020">2020</date>
			<biblScope unit="page" from="28" to="33" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title level="m" type="main">A method for explaining Bayesian networks for legal evidence with scenarios. Artificial Intelligence and Law</title>
		<author>
			<persName><forename type="first">C</forename><surname>Vlek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Prakken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Renooij</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Verheij</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10506-016-9183-4</idno>
		<imprint>
			<date type="published" when="2016">2016</date>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="285" to="324" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Explainable Bayesian Network Query Results via Natural Language Generation Systems</title>
		<author>
			<persName><forename type="first">J</forename><surname>Keppens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Proceedings of the Seventeenth International Conference on Artificial Intelligence and Law. ICAIL &apos;19</title>
		<meeting>the Seventeenth International Conference on Artificial Intelligence and Law. ICAIL &apos;19<address><addrLine>New York, NY, USA</addrLine></address></meeting>
		<imprint>
			<publisher>Association for Computing Machinery</publisher>
			<date type="published" when="2019">2019</date>
			<biblScope unit="page" from="42" to="51" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<title level="m" type="main">Modeling COVID-19 disease processes by eliciting causal BNs</title>
		<author>
			<persName><surname>Mascaro</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">A Progressive Explanation of Inference in &apos;Hybrid&apos; Bayesian Networks for Supporting Clinical Decision Making</title>
		<author>
			<persName><forename type="first">E</forename><surname>Kyrimi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Marsh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Probabilistic Graphical Models -Eighth International Conference (PGM 2016)</title>
		<editor>
			<persName><forename type="first">A</forename><surname>Antonucci</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">G</forename><surname>Corani</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>De Campos</surname></persName>
		</editor>
		<meeting><address><addrLine>Lugano, Switzerland</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2016">September 6-9, 2016. 2016</date>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="275" to="286" />
		</imprint>
	</monogr>
	<note>JMLR</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">BARD: A Structured Technique for Group Elicitation of Bayesian Networks to Support Analytic Reasoning</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Nyberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Nicholson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Korb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wybrow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Zukerman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mascaro</surname></persName>
		</author>
		<idno type="DOI">10.1111/risa.13759</idno>
	</analytic>
	<monogr>
		<title level="j">Risk Analysis</title>
		<imprint>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>Special Issue: Bayesian networks for risk analysis and decision-support</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Human-Centric Justification of Machine Learning Predictions</title>
		<author>
			<persName><forename type="first">O</forename><surname>Biran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mckeown</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Proceedings of the Twenty-Sixth International Joint Conference on Artificial Intelligence</title>
		<meeting>the Twenty-Sixth International Joint Conference on Artificial Intelligence</meeting>
		<imprint>
			<date type="published" when="2017">2017</date>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1461" to="1467" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Improving the accuracy of medical diagnosis with causal machine learning</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Richens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Johri</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41467-020-17419-7</idno>
	</analytic>
	<monogr>
		<title level="j">Nature Communications</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">3923</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Learning Hybrid Bayesian Networks by MML</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>O'donnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Allison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Korb</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">AI 2006: Advances in Artificial Intelligence</title>
		<editor>
			<persName><forename type="first">A</forename><surname>Sattar</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">B</forename><surname>Kang</surname></persName>
		</editor>
		<meeting><address><addrLine>Berlin</addrLine></address></meeting>
		<imprint>
			<publisher>Springer</publisher>
			<date type="published" when="2006">2006</date>
			<biblScope unit="page" from="192" to="203" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Bayesian belief nets for managing expert judgement and modelling reliability</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Sigurdsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Walls</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Quigley</surname></persName>
		</author>
		<idno type="DOI">10.1002/qre.410</idno>
	</analytic>
	<monogr>
		<title level="j">Quality and Reliability Engineering International</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="181" to="190" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<monogr>
		<title level="m" type="main">Bayesian networks in reliability. Reliability Engineering and System Safety</title>
		<author>
			<persName><forename type="first">H</forename><surname>Langseth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Portinale</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2007">2007</date>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="92" to="108" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Modelling spatial and temporal changes with GIS and Spatial and Dynamic Bayesian Networks</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">E</forename><surname>Chee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wilkinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Nicholson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Quintana-Ascencio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Fauth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hall</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.envsoft.2016.04.012</idno>
	</analytic>
	<monogr>
		<title level="j">Environmental Modelling &amp; Software</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="108" to="120" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Individual versus group decision making: Jurors&apos; reliance on central and peripheral information to evaluate expert testimony</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Salerno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Bottoms</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Peter-Hagene</forename><surname>Lc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLOS One</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">183580</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Are groups more rational than individuals? A review of interactive decision making in groups</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kugler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Kausel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Kocher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Wiley Interdisciplinary Reviews: Cognitive Science</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="471" to="482" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Groups make better self-interested decisions</title>
		<author>
			<persName><forename type="first">G</forename><surname>Charness</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sutter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Economic Perspectives</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="157" to="176" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">The group matters: A review of processes and outcomes in intelligence analysis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Straus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Bruce</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Group Dynamics: Theory</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">128</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>Research, and Practice</note>
</biblStruct>

<biblStruct xml:id="b37">
	<monogr>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Hackman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Katz</surname></persName>
		</author>
		<author>
			<persName><surname>32</surname></persName>
		</author>
		<title level="m">Group behavior and performance</title>
		<editor>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Fiske</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Gilbert</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">G</forename><surname>Lindzey</surname></persName>
		</editor>
		<meeting><address><addrLine>New York</addrLine></address></meeting>
		<imprint>
			<publisher>Wiley</publisher>
			<date type="published" when="2010">2010</date>
			<biblScope unit="page" from="1208" to="1251" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">The Robust Beauty of Majority Rules in Group Decisions</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hastie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kameda</surname></persName>
		</author>
		<idno type="DOI">10.1037/0033-295X.112.2.494</idno>
	</analytic>
	<monogr>
		<title level="j">Psychological review</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="494" to="508" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<monogr>
		<author>
			<persName><forename type="first">D</forename><surname>Kahneman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Slovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tversky</surname></persName>
		</author>
		<title level="m">Judgment Under Uncertainty: Heuristics and Biases</title>
		<meeting><address><addrLine>New York</addrLine></address></meeting>
		<imprint>
			<publisher>Cambridge University Press</publisher>
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Counteracting anchoring effects in group decision making</title>
		<author>
			<persName><forename type="first">M</forename><surname>Stettinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Felfernig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Leitner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Reiterer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">23rd International Conference on User Modeling, Adaptation, and Personalization</title>
		<meeting><address><addrLine>Cham</addrLine></address></meeting>
		<imprint>
			<publisher>Springer</publisher>
			<date type="published" when="2015">2015. 2015</date>
			<biblScope unit="page" from="118" to="130" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Errors in creative thought? Cognitive biases in a complex processing activity</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Mumford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Blair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dailey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Leritz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Osburn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Journal of Creative Behavior</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="75" to="109" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Avoiding groupthink: Whereas weakly identified members remain silent, strongly identified members dissent about collective problems</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Packer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychological Science</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="546" to="548" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Is Out of Sight, Out of Mind? An Empirical Study of Social Loafing in Technology-Supported Groups</title>
		<author>
			<persName><forename type="first">L</forename><surname>Chidambaram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Tung</surname></persName>
		</author>
		<idno type="DOI">10.1287/isre.1050.0051</idno>
	</analytic>
	<monogr>
		<title level="j">Systems Research</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="149" to="168" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<monogr>
		<title level="m" type="main">The Delphi Method: Techniques and Applications</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Linstone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Turoff</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1975-02-14">1975. February 14, 2022 31/32</date>
			<publisher>Addison-Wesley</publisher>
			<pubPlace>London</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<monogr>
		<title level="m" type="main">Modeling COVID-19 disease processes by eliciting causal BNs</title>
		<author>
			<persName><surname>Mascaro</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Delphi: a reevaluation of research and theory</title>
		<author>
			<persName><forename type="first">G</forename><surname>Rowe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bolger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Technological Forecasting and Social Change</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="235" to="251" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Network fragments: Representing knowledge for constructing probabilistic models</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Laskey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Mahoney</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Proceedings of the Thirteenth Conference on Uncertainty in Artificial Intelligence,. UAI&apos;97</title>
		<meeting>the Thirteenth Conference on Uncertainty in Artificial Intelligence,. UAI&apos;97<address><addrLine>San Francisco</addrLine></address></meeting>
		<imprint>
			<publisher>Morgan Kaufmann</publisher>
			<date type="published" when="1997">1997</date>
			<biblScope unit="page" from="334" to="341" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Network engineering for agile belief network models</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Laskey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Mahoney</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">IEEE Transactions on Knowledge and Data Engineering</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="487" to="498" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<monogr>
		<title level="m" type="main">Ontology and Bayesian decision networks for supporting the meteorological forecasting process</title>
		<author>
			<persName><forename type="first">T</forename><surname>Boneh</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>PhD thesis</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">The &quot;Jury Fallacy&quot; and the use of Bayesian Networks to present Probabilistic Legal Arguments</title>
		<author>
			<persName><forename type="first">N</forename><surname>Fenton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Neil</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mathematics Today</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="61" to="102" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">A spiral model of software development and enhancement</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Boehm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Computer</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="61" to="72" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<monogr>
		<title level="m" type="main">Object-Oriented Programming; An Evolutionary Approach. 2nd ed. USA</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Cox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Novobilski</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1991">1991</date>
			<publisher>Addison-Wesley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Application of a technique for research and development program evaluation</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Malcolm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Roseboom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Fazar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Operations Research</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="646" to="649" />
			<date type="published" when="1959">1959</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Overconfidence in interval estimates</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Soll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Klayman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Experimental Psychology Learning Memory and Cognition</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="299" to="314" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Reducing overconfidence in the interval judgments of experts</title>
		<author>
			<persName><forename type="first">A</forename><surname>Fidler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mcbride</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Flander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cumming</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Burgman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Risk Analysis</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="512" to="523" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">A practical guide to structured expert elicitation using the IDEA protocol</title>
		<author>
			<persName><forename type="first">V</forename><surname>Hemming</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Burgman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Hanea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Mcbride</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Wintle</surname></persName>
		</author>
		<idno type="DOI">10.1111/2041-210X.12857</idno>
	</analytic>
	<monogr>
		<title level="j">Methods in Ecology and Evolution</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="169" to="180" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">The bowtie method: A review</title>
		<author>
			<persName><forename type="first">A</forename><surname>De Ruijter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Guldenmund</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ssci.2016.03.001</idno>
	</analytic>
	<monogr>
		<title level="j">Safety Science</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="211" to="218" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Bridging the gaps in test interpretation of SARS-CoV-2 through Bayesian network modelling</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Foley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ramsay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Woodberry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mascaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Nicholson</surname></persName>
		</author>
		<idno type="DOI">10.1017/S0950268821001357</idno>
	</analytic>
	<monogr>
		<title level="j">Epidemiology and Infection</title>
		<imprint>
			<biblScope unit="volume">149</biblScope>
			<biblScope unit="page">166</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">The pathophysiology of &apos;happy&apos; hypoxemia in COVID-19</title>
		<author>
			<persName><forename type="first">S</forename><surname>Dhont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Derom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Van</forename><surname>Braeckel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Depuydt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lambrecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">N</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Respiratory Research</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="9" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Cause and Norm</title>
		<author>
			<persName><forename type="first">C</forename><surname>Hitchcock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Knobe</surname></persName>
		</author>
		<idno type="DOI">10.5840/jphil20091061128</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Philosophy</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="587" to="612" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Use of directed acyclic graphs (DAGs) to identify confounders in applied health research: review and recommendations</title>
		<author>
			<persName><forename type="first">Pwg</forename><surname>Tennant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Murray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">F</forename><surname>Arnold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Berrie</forename><forename type="middle">L</forename><surname>Fox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Gadd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename></persName>
		</author>
		<idno type="DOI">10.1093/ije/dyaa213</idno>
	</analytic>
	<monogr>
		<title level="j">International Journal of Epidemiology</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="620" to="632" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients</title>
		<author>
			<persName><forename type="first">L</forename><surname>Zou</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMc2001737</idno>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<date type="published" when="2020-02">Feb. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19</title>
		<author>
			<persName><forename type="first">J</forename><surname>Meinhardt</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41593-020-00758-5</idno>
	</analytic>
	<monogr>
		<title level="j">Nat. Neurosci</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">2</biblScope>
			<date type="published" when="2021-02">Feb. 2021</date>
			<pubPlace>Art</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Brann</surname></persName>
		</author>
		<idno type="DOI">10.1126/sciadv.abc5801</idno>
	</analytic>
	<monogr>
		<title level="j">Sci. Adv</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">31</biblScope>
			<date type="published" when="2020-07">Jul. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P Y</forename><surname>Hui</surname></persName>
		</author>
		<idno type="DOI">10.1016/S2213-2600</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet Respir. Med</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="30193" to="30194" />
			<date type="published" when="2020-07">Jul. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">COVID-19: the vasculature unleashed</title>
		<author>
			<persName><forename type="first">L.-A</forename><surname>Teuwen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Geldhof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pasut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Carmeliet</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41577-020-0343-0</idno>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Immunol</title>
		<imprint>
			<biblScope unit="page" from="1" to="3" />
			<date type="published" when="2020-05">May 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">A cross-talk between epithelium and endothelium mediates human alveolarcapillary injury during SARS-CoV-2 infection</title>
		<author>
			<persName><forename type="first">P</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41419-020-03252-9</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Death Dis</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">12</biblScope>
			<date type="published" when="2020-12">Dec. 2020</date>
			<pubPlace>Art</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19</title>
		<author>
			<persName><forename type="first">H</forename><surname>Chu</surname></persName>
		</author>
		<idno type="DOI">10.1093/cid/ciaa410</idno>
	</analytic>
	<monogr>
		<title level="j">Clin. Infect. Dis</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1400" to="1409" />
			<date type="published" when="2020-09">Sep. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Endothelial cells and SARS-CoV-2: An intimate relationship</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Barbosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Gonรงalves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>De Araujo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">V</forename><surname>De</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Rosario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">P</forename><surname>Ferrer</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.vph.2021.106829</idno>
	</analytic>
	<monogr>
		<title level="j">Vascul. Pharmacol</title>
		<imprint>
			<date type="published" when="2021-01">Jan. 2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Endothelial cell infection and endotheliitis in COVID-19</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Varga</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(20)30937-5</idno>
	</analytic>
	<monogr>
		<title level="j">The Lancet</title>
		<imprint>
			<biblScope unit="volume">395</biblScope>
			<biblScope unit="issue">10234</biblScope>
			<biblScope unit="page" from="1417" to="1418" />
			<date type="published" when="2020-05">May 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Bermejo-Martin</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13054-020-03398-0</idno>
	</analytic>
	<monogr>
		<title level="j">Crit. Care</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">691</biblScope>
			<date type="published" when="2020-12">Dec. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Pulmonary capillary leak syndrome following COVID-19 virus infection</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bahloul</surname></persName>
		</author>
		<idno type="DOI">10.1002/jmv.26152</idno>
	</analytic>
	<monogr>
		<title level="j">J. Med. Virol</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection</title>
		<author>
			<persName><forename type="first">S</forename><surname>Pons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fodil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Azoulay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zafrani</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13054-020-03062-7</idno>
	</analytic>
	<monogr>
		<title level="j">Care</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<date type="published" when="2020-06">Jun. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Productive Cough in Children and Adolescents -View from Primary Health Care System</title>
		<author>
			<persName><forename type="first">E</forename><surname>Begic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Begic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dobraca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hasanbegovic</surname></persName>
		</author>
		<idno type="DOI">10.5455/medarh.2017.71.66-68</idno>
	</analytic>
	<monogr>
		<title level="j">Med. Arch</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="66" to="68" />
			<date type="published" when="2017-02">Feb. 2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Causes of chronic productive cough: An approach to management</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Harrison</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.rmed.2015.05.020</idno>
	</analytic>
	<monogr>
		<title level="j">Respir. Med</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1105" to="1113" />
			<date type="published" when="2015-09">Sep. 2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Pathophysiology of SARS-CoV-2 in Lung of Diabetic Patients</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Oliveira</surname></persName>
		</author>
		<idno type="DOI">10.3389/fphys.2020.587013</idno>
	</analytic>
	<monogr>
		<title level="j">Front. Physiol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Postmortem Examination of Patients With COVID-19</title>
		<author>
			<persName><forename type="first">T</forename><surname>Schaller</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.2020.8907</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<date type="published" when="2020-05">May 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Skeletal Muscle Wasting and Function Impairment in Intensive Care Patients With Severe COVID-19</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>De Andrade-Junior</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">C D</forename><surname>De Salles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M M</forename><surname>De Brito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pastore-Junior</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Righetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">P</forename><surname>Yamaguti</surname></persName>
		</author>
		<idno type="DOI">10.3389/fphys.2021.640973</idno>
	</analytic>
	<monogr>
		<title level="j">Front. Physiol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">2021</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Vertical gradient of regional lung inflation in adult respiratory distress syndrome</title>
		<author>
			<persName><forename type="first">P</forename><surname>Pelosi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>D'andrea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Vitale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pesenti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gattinoni</surname></persName>
		</author>
		<idno type="DOI">10.1164/ajrccm.149.1.8111603</idno>
	</analytic>
	<monogr>
		<title level="j">Am. J. Respir. Crit. Care Med</title>
		<imprint>
			<biblScope unit="volume">149</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="8" to="13" />
			<date type="published" when="1994-01">Jan. 1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Emerging Mechanisms of Pulmonary Vasoconstriction in SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) and Potential Therapeutic Targets</title>
		<author>
			<persName><forename type="first">H</forename><surname>Karmouty-Quintana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Thandavarayan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Keller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sahay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Pandit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Akkanti</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijms21218081</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Mol. Sci</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">21</biblScope>
			<date type="published" when="2020-10">Oct. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19</title>
		<author>
			<persName><forename type="first">M</forename><surname>Dolhnikoff</surname></persName>
		</author>
		<idno type="DOI">10.1111/jth.14844</idno>
	</analytic>
	<monogr>
		<title level="j">J. Thromb. Haemost</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Novel insights on the pulmonary vascular consequences of COVID-19</title>
		<author>
			<persName><forename type="first">F</forename><surname>Potus</surname></persName>
		</author>
		<idno type="DOI">10.1152/ajplung.00195.2020</idno>
	</analytic>
	<monogr>
		<title level="m">L277-L288</title>
		<imprint>
			<date type="published" when="2020-08">Aug. 2020</date>
			<biblScope unit="volume">319</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">The clinical spectrum of pulmonary thromboembolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: A European case series</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Sakr</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jcrc.2020.09.021</idno>
	</analytic>
	<monogr>
		<title level="j">J. Crit. Care</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="39" to="44" />
			<date type="published" when="2021-02">Feb. 2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ackermann</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa2015432</idno>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">0</biblScope>
			<biblScope unit="issue">0</biblScope>
			<date type="published" when="2020-05">May 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Pulmonary Embolism and Deep Vein Thrombosis in COVID-19: A Systematic Review and Meta-Analysis</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Suh</surname></persName>
		</author>
		<idno type="DOI">10.1148/radiol.2020203557</idno>
	</analytic>
	<monogr>
		<title level="j">Radiology</title>
		<imprint>
			<biblScope unit="volume">298</biblScope>
			<biblScope unit="issue">2</biblScope>
			<date type="published" when="2020-12">Dec. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Dhawan</surname></persName>
		</author>
		<idno type="DOI">10.1016/S2213-2600</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet Respir. Med</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="30407" to="30407" />
			<date type="published" when="2021-01">Jan. 2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome</title>
		<author>
			<persName><forename type="first">F</forename><surname>Scudiero</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.thromres.2020.11.017</idno>
	</analytic>
	<monogr>
		<title level="j">Thromb. Res</title>
		<imprint>
			<biblScope unit="volume">198</biblScope>
			<biblScope unit="page" from="34" to="39" />
			<date type="published" when="2021-02">Feb. 2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study</title>
		<author>
			<persName><forename type="first">G</forename><surname>Grasselli</surname></persName>
		</author>
		<idno type="DOI">10.1016/S2213-2600(20)30370-2</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet Respir. Med</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1201" to="1208" />
			<date type="published" when="2020-12">Dec. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Silent&apos; Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Bickler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Feiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Lipnick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Mckleroy</surname></persName>
		</author>
		<idno type="DOI">10.1097/ALN.0000000000003578</idno>
	</analytic>
	<monogr>
		<title level="j">Anesthesiology</title>
		<imprint>
			<date type="published" when="2020-09">Sep. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">The pathophysiology of &apos;happy&apos; hypoxemia in COVID-19</title>
		<author>
			<persName><forename type="first">S</forename><surname>Dhont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Derom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Van Braeckel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Depuydt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">N</forename><surname>Lambrecht</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12931-020-01462-5</idno>
	</analytic>
	<monogr>
		<title level="j">Respir. Res</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">1</biblScope>
			<date type="published" when="2020-07">Jul. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dualenergy CT</title>
		<author>
			<persName><forename type="first">M</forename><surname>Lang</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1473-3099</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect. Dis</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="30367" to="30371" />
			<date type="published" when="2020-12">Dec. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">COVID-19 and Hypercoagulability: A Review</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kichloo</surname></persName>
		</author>
		<idno type="DOI">10.1177/1076029620962853</idno>
	</analytic>
	<monogr>
		<title level="j">Clin. Appl. Thromb</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page">1076029620962853</biblScope>
			<date type="published" when="2020-01">Jan. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">COVID-19 and Multiorgan Response</title>
		<author>
			<persName><forename type="first">S</forename><surname>Zaim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Chong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Sankaranarayanan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Harky</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cpcardiol.2020.100618</idno>
	</analytic>
	<monogr>
		<title level="j">Curr. Probl. Cardiol</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page">100618</biblScope>
			<date type="published" when="2020-08">Aug. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Pulmonary Arterial Hypertension: The Clinical Syndrome</title>
		<author>
			<persName><forename type="first">Y.-C</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Potoka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Champion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Mora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Gladwin</surname></persName>
		</author>
		<idno type="DOI">10.1161/CIRCRESAHA.115.301146</idno>
	</analytic>
	<monogr>
		<title level="j">Circ. Res</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="115" to="130" />
			<date type="published" when="2014-06">Jun. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Physiologic Improvement in Respiratory Acidosis Using Extracorporeal Co2 Removal With Hemolung Respiratory Assist System in the Management of Severe Respiratory Failure From Coronavirus Disease 2019</title>
		<author>
			<persName><forename type="first">B</forename><surname>Akkanti</surname></persName>
		</author>
		<idno type="DOI">10.1097/CCE.0000000000000372</idno>
	</analytic>
	<monogr>
		<title level="j">Crit. Care Explor</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">3</biblScope>
			<date type="published" when="2021-03">Mar. 2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">Hypoxia, HIF-1ฮฑ, and COVID-19: from pathogenic factors to potential therapeutic targets</title>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">O</forename><surname>Serebrovska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">Y</forename><surname>Chong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">V</forename><surname>Serebrovska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">V</forename><surname>Tumanovska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Xi</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41401-020-00554-8</idno>
	</analytic>
	<monogr>
		<title level="j">Acta Pharmacol. Sin</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">12</biblScope>
			<date type="published" when="2020-12">Dec. 2020</date>
			<pubPlace>Art</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Clinical Features of Fatalities in Patients With COVID-19</title>
		<author>
			<persName><forename type="first">Y.-J</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y.-J</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z.-C</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P.-X</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1017/dmp.2020.235</idno>
	</analytic>
	<monogr>
		<title level="j">Disaster Med. Public Health Prep</title>
		<imprint>
			<biblScope unit="page" from="1" to="3" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes</title>
		<author>
			<persName><forename type="first">W</forename><surname>Sungnak</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41591-020-0868-6</idno>
	</analytic>
	<monogr>
		<title level="j">Nature Medicine</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">5</biblScope>
			<date type="published" when="2020-05">May 2020</date>
			<pubPlace>Art</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Endothelial cell infection and endotheliitis in COVID-19</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Varga</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(20)30937-5</idno>
	</analytic>
	<monogr>
		<title level="j">The Lancet</title>
		<imprint>
			<biblScope unit="volume">395</biblScope>
			<biblScope unit="issue">10234</biblScope>
			<biblScope unit="page" from="1417" to="1418" />
			<date type="published" when="2020-05">May 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P Y</forename><surname>Hui</surname></persName>
		</author>
		<idno type="DOI">10.1016/S2213-2600(20)30193-4</idno>
	</analytic>
	<monogr>
		<title level="j">The Lancet Respiratory Medicine</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="687" to="695" />
			<date type="published" when="2020-07">Jul. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">Novel insights on the pulmonary vascular consequences of COVID-19</title>
		<author>
			<persName><forename type="first">F</forename><surname>Potus</surname></persName>
		</author>
		<idno type="DOI">10.1152/ajplung.00195.2020</idno>
	</analytic>
	<monogr>
		<title level="m">L277-L288</title>
		<imprint>
			<date type="published" when="2020-08">Aug. 2020</date>
			<biblScope unit="volume">319</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Dhawan</surname></persName>
		</author>
		<idno type="DOI">10.1016/S2213-2600(20)30407-0</idno>
	</analytic>
	<monogr>
		<title level="j">The Lancet Respiratory Medicine</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="107" to="116" />
			<date type="published" when="2021-01">Jan. 2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">Pulmonary Arterial Hypertension: The Clinical Syndrome</title>
		<author>
			<persName><forename type="first">Y.-C</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Potoka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Champion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Mora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Gladwin</surname></persName>
		</author>
		<idno type="DOI">10.1161/CIRCRESAHA.115.301146</idno>
	</analytic>
	<monogr>
		<title level="j">Circ Res</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="115" to="130" />
			<date type="published" when="2014-06">Jun. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">Continuous positive airway pressure in COVID-19 patients with moderate-tosevere respiratory failure</title>
		<author>
			<persName><forename type="first">C</forename><surname>Brusasco</surname></persName>
		</author>
		<idno type="DOI">10.1183/13993003.02524-2020</idno>
	</analytic>
	<monogr>
		<title level="j">European Respiratory Journal</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">2</biblScope>
			<date type="published" when="2021-02">Feb. 2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19</title>
		<author>
			<persName><forename type="first">H</forename><surname>Chu</surname></persName>
		</author>
		<idno type="DOI">10.1093/cid/ciaa410</idno>
	</analytic>
	<monogr>
		<title level="j">Clinical Infectious Diseases</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1400" to="1409" />
			<date type="published" when="2020-09">Sep. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">Viral Pathogenesis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Baron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Albrecht</surname></persName>
		</author>
		<ptr target="http://www.ncbi.nlm.nih.gov/books/NBK8149/" />
	</analytic>
	<monogr>
		<title level="m">Medical Microbiology, 4</title>
		<editor>
			<persName><forename type="first">S</forename><surname>Baron</surname></persName>
		</editor>
		<meeting><address><addrLine>Galveston (TX</addrLine></address></meeting>
		<imprint>
			<date type="published" when="1996-09-20">1996. Sep. 20, 2021</date>
		</imprint>
		<respStmt>
			<orgName>University of Texas Medical Branch at Galveston</orgName>
		</respStmt>
	</monogr>
	<note>th ed</note>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Pathology and Pathogenesis of Severe Acute Respiratory Syndrome</title>
		<author>
			<persName><forename type="first">J</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Korteweg</surname></persName>
		</author>
		<idno type="DOI">10.2353/ajpath.2007.061088</idno>
	</analytic>
	<monogr>
		<title level="j">The American Journal of Pathology</title>
		<imprint>
			<biblScope unit="volume">170</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1136" to="1147" />
			<date type="published" when="2007-04">Apr. 2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">Silent&apos; Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Bickler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Feiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Lipnick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Mckleroy</surname></persName>
		</author>
		<idno type="DOI">10.1097/ALN.0000000000003578</idno>
	</analytic>
	<monogr>
		<title level="j">Anesthesiology</title>
		<imprint>
			<date type="published" when="2020-09">Sep. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">The pathophysiology of &apos;happy&apos; hypoxemia in COVID-19</title>
		<author>
			<persName><forename type="first">S</forename><surname>Dhont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Derom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Van Braeckel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Depuydt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">N</forename><surname>Lambrecht</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12931-020-01462-5</idno>
	</analytic>
	<monogr>
		<title level="j">Respiratory Research</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">1</biblScope>
			<date type="published" when="2020-07">Jul. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization</title>
		<author>
			<persName><forename type="first">S</forename><surname>Caravita</surname></persName>
		</author>
		<idno type="DOI">10.1002/ejhf.2058</idno>
	</analytic>
	<monogr>
		<title level="j">European Journal of Heart Failure</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2228" to="2237" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">Glycocalyx and sepsisinduced alterations in vascular permeability</title>
		<author>
			<persName><forename type="first">C</forename><surname>Chelazzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Villa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mancinelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>De Gaudio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Adembri</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13054-015-0741-z</idno>
	</analytic>
	<monogr>
		<title level="j">Critical Care</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">26</biblScope>
			<date type="published" when="2015-12">Dec. 2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b112">
	<monogr>
		<title level="m" type="main">Full article: A multidisciplinary consensus on dehydration: definitions, diagnostic methods and clinical implications</title>
		<idno type="DOI">10.1080/07853890.2019.1628352</idno>
		<ptr target="https://www.tandfonline.com/doi/full/10.1080/07853890.2019.1628352" />
		<imprint>
			<date type="published" when="2021-09-20">Sep. 20, 2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<ptr target="https://www.ncbi.nlm.nih.gov/books/NBK538308/" />
	</analytic>
	<monogr>
		<title level="m">Peripheral Vascular Resistance -StatPearls -NCBI Bookshelf</title>
		<imprint>
			<date type="published" when="2021-09-24">accessed Sep. 24, 2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main">Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19)</title>
		<author>
			<persName><forename type="first">G</forename><surname>Lippi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>South</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Henry</surname></persName>
		</author>
		<idno type="DOI">10.1177/0004563220922255</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Clin Biochem</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="262" to="265" />
			<date type="published" when="2020-05">May 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main">Renal function, electrolytes, and congestion monitoring in heart failure</title>
		<author>
			<persName><forename type="first">P</forename><surname>Rossignol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Coats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Chioncel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Spoletini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rosano</surname></persName>
		</author>
		<idno type="DOI">10.1093/eurheartj/suz220</idno>
	</analytic>
	<monogr>
		<title level="j">European Heart Journal Supplements</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">Supplement_M</biblScope>
			<date type="published" when="2019-12">Dec. 2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">Pathophysiology and Treatment of Gastrointestinal Motility Disorders in the Acutely Ill</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Deane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Chapman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Blaser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Mcclave</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Emmanuel</surname></persName>
		</author>
		<idno type="DOI">10.1002/ncp.10199</idno>
	</analytic>
	<monogr>
		<title level="j">Nutrition in Clinical Practice</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="23" to="36" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main">Metabolic acidosis: pathophysiology, diagnosis and management</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Kraut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Madias</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrneph.2010.33</idno>
	</analytic>
	<monogr>
		<title level="j">Nature Reviews Nephrology</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">5</biblScope>
			<date type="published" when="2010-05">May 2010</date>
			<pubPlace>Art</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main">Hemodynamic consequences of severe lactic acidosis in shock states: from bench to bedside</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kimmoun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Novy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Auchet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ducrocq</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Levy</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13054-015-0896-7</idno>
	</analytic>
	<monogr>
		<title level="j">Crit Care</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page">175</biblScope>
			<date type="published" when="2015-04">Apr. 2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b119">
	<monogr>
		<title level="m" type="main">Hypertension and Electrolyte Disorders in Patients with COVID-19</title>
		<author>
			<persName><forename type="first">J.-H</forename><surname>Lim</surname></persName>
		</author>
		<idno type="DOI">10.5049/EBP.2020.18.2.23</idno>
		<imprint>
			<date type="published" when="2020-12">Dec. 2020</date>
			<publisher>Electrolyte Blood Press</publisher>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="23" to="30" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19</title>
		<author>
			<persName><forename type="first">M</forename><surname>Dolhnikoff</surname></persName>
		</author>
		<idno type="DOI">10.1111/jth.14844</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Thrombosis and Haemostasis</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main">The clinical spectrum of pulmonary thromboembolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: A European case series</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Sakr</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jcrc.2020.09.021</idno>
	</analytic>
	<monogr>
		<title level="j">J Crit Care</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="39" to="44" />
			<date type="published" when="2021-02">Feb. 2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main">Thrombosis and COVID-19 pneumonia: the clot thickens!</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mccabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Garfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Wort</surname></persName>
		</author>
		<idno type="DOI">10.1183/13993003.01608-2020</idno>
	</analytic>
	<monogr>
		<title level="j">European Respiratory Journal</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">1</biblScope>
			<date type="published" when="2020-07">Jul. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main">Effects of hypercapnia on peripheral vascular reactivity in elderly patients with acute exacerbation of chronic obstructive pulmonary disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>De Matthaeis</surname></persName>
		</author>
		<idno type="DOI">10.2147/CIA.S57548</idno>
	</analytic>
	<monogr>
		<title level="j">Clin Interv Aging</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="871" to="878" />
			<date type="published" when="2014-05">May 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b124">
	<monogr>
		<title level="m" type="main">Cerebral Circulation: XII. The Effect on Pial Vessels of Variations in The Oxygen and Carbon Dioxide Content of The Blood | Archives of Neurology &amp; Psychiatry | JAMA Network</title>
		<ptr target="https://jamanetwork.com/journals/archneurpsyc/article-abstract/644583" />
		<imprint>
			<date type="published" when="2021-09-24">accessed Sep. 24, 2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main">Hypoxia, vascular smooth muscles and endothelium</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Vanhoutte</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.apsb.2012.12.007</idno>
	</analytic>
	<monogr>
		<title level="j">Acta Pharmaceutica Sinica B</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="7" />
			<date type="published" when="2013-02">Feb. 2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main">Coagulopathy and sepsis: Pathophysiology, clinical manifestations and treatment</title>
		<author>
			<persName><forename type="first">M</forename><surname>Giustozzi</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.blre.2021.100864</idno>
	</analytic>
	<monogr>
		<title level="j">Blood Reviews</title>
		<imprint>
			<biblScope unit="page">100864</biblScope>
			<date type="published" when="2021-06">Jun. 2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b127">
	<analytic>
		<title level="a" type="main">Assessment and classification of patients with myocardial injury and infarction in clinical practice</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Chapman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Adamson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Mills</surname></persName>
		</author>
		<idno type="DOI">10.1136/heartjnl-2016-309530</idno>
	</analytic>
	<monogr>
		<title level="j">Heart</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="10" to="18" />
			<date type="published" when="2017-01">Jan. 2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b128">
	<analytic>
		<title level="a" type="main">Myocyte-Specific Upregulation of ACE2 in Cardiovascular Disease</title>
		<author>
			<persName><forename type="first">Tucker</forename><surname>Nathan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
		<idno type="DOI">10.1161/CIRCULATIONAHA.120.047911</idno>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">142</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="708" to="710" />
			<date type="published" when="2020-08">Aug. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b129">
	<analytic>
		<title level="a" type="main">Covid-19 and the cardiovascular system: a comprehensive review</title>
		<ptr target="https://www.nature.com/articles/s41371-020-0387-4" />
	</analytic>
	<monogr>
		<title level="j">Journal of Human Hypertension</title>
		<imprint>
			<date type="published" when="2021-09-20">accessed Sep. 20, 2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b130">
	<analytic>
		<title level="a" type="main">Heart failure and COVID-19</title>
		<author>
			<persName><forename type="first">F</forename><surname>Bader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Manla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Atallah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Starling</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10741-020-10008-2</idno>
	</analytic>
	<monogr>
		<title level="j">Heart Fail Rev</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2021-01">Jan. 2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b131">
	<analytic>
		<title level="a" type="main">Liver diseases in COVID-19: Etiology, treatment and prognosis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H.-C</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L.-J</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.3748/wjg.v26.i19.2286</idno>
	</analytic>
	<monogr>
		<title level="j">World J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">19</biblScope>
			<biblScope unit="page" from="2286" to="2293" />
			<date type="published" when="2020-05">May 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b132">
	<monogr>
		<title level="m" type="main">COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies</title>
		<ptr target="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132016/" />
		<imprint>
			<date type="published" when="2021-09-24">accessed Sep. 24, 2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b133">
	<analytic>
		<title level="a" type="main">Acid-base status and its clinical implications in critically ill patients with cirrhosis, acute-on-chronic liver failure and without liver disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>Drolz</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13613-018-0391-9</idno>
	</analytic>
	<monogr>
		<title level="j">Annals of Intensive Care</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">48</biblScope>
			<date type="published" when="2018-04">Apr. 2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b134">
	<analytic>
		<title level="a" type="main">Critically Ill COVID-19 Patients with Acute Kidney Injury Have Reduced Renal Blood Flow and Perfusion Despite Preserved Cardiac Function: A Case-Control Study Using Contrast-Enhanced Ultrasound</title>
		<author>
			<persName><forename type="first">J</forename><surname>Watchorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Joslin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bramham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Hutchings</surname></persName>
		</author>
		<idno type="DOI">10.1097/SHK.0000000000001659</idno>
	</analytic>
	<monogr>
		<title level="j">Shock</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="479" to="487" />
			<date type="published" when="2021-04">Apr. 2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b135">
	<analytic>
		<title level="a" type="main">SARS-CoV-2 renal tropism associates with acute kidney injury</title>
		<author>
			<persName><forename type="first">F</forename><surname>Braun</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(20)31759-1</idno>
	</analytic>
	<monogr>
		<title level="j">The Lancet</title>
		<imprint>
			<biblScope unit="volume">0</biblScope>
			<biblScope unit="issue">0</biblScope>
			<date type="published" when="2020-08">Aug. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b136">
	<monogr>
		<title level="m" type="main">Bone Marrow and Peripheral Blood Findings in Patients Infected by SARS-CoV-2 | American Journal of Clinical Pathology | Oxford Academic</title>
		<ptr target="https://academic.oup.com/ajcp/article/155/5/627/6121360" />
		<imprint>
			<date type="published" when="2021-09-20">accessed Sep. 20, 2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b137">
	<analytic>
		<title level="a" type="main">The gut in COVID-19</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Reintam</forename><surname>Blaser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gunst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Arabi</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00134-021-06461-8</idno>
	</analytic>
	<monogr>
		<title level="j">Intensive Care Med</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1024" to="1027" />
			<date type="published" when="2021-09">Sep. 2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b138">
	<analytic>
		<title level="a" type="main">ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults</title>
		<author>
			<persName><forename type="first">L</forename><surname>Pironi</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.clnu.2014.08.017</idno>
	</analytic>
	<monogr>
		<title level="j">Clinical Nutrition</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="171" to="180" />
			<date type="published" when="2015-04">Apr. 2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b139">
	<analytic>
		<title level="a" type="main">Brainstem dysfunction in critically ill patients</title>
		<author>
			<persName><forename type="first">S</forename><surname>Benghanem</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13054-019-2718-9</idno>
	</analytic>
	<monogr>
		<title level="j">Critical Care</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">5</biblScope>
			<date type="published" when="2020-01">Jan. 2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b140">
	<analytic>
		<title level="a" type="main">Understanding brain dysfunction in sepsis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Sonneville</surname></persName>
		</author>
		<idno type="DOI">10.1186/2110-5820-3-15</idno>
	</analytic>
	<monogr>
		<title level="j">Ann. Intensive Care</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">15</biblScope>
			<date type="published" when="2013-05">May 2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b141">
	<monogr>
		<title level="m" type="main">Hepatic Encephalopathy | NEJM</title>
		<idno type="DOI">10.1056/NEJMra1600561</idno>
		<ptr target="https://www.nejm.org/doi/full/10.1056/NEJMra1600561" />
		<imprint>
			<date type="published" when="2021-09-24">accessed Sep. 24, 2021</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
